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 INTRODUCTION 
     Diabetes mellitus is a very common endocrinopathy, and occurs as a result of absolute   
or relative deficiency in insulin. It is one of the main threats to human health in the 21st 
century, being a leading cause of death.  Several distinct types of DM exist and are 
caused by a complex interaction of genetic and environmental factors (3). Diabetes is 
associated with various microvascular, macrovascular, and metabolic complications (2). 
     Hypomagnesemia has been proposed to be correlated to diabetes, its pathogenesis, 
complications and comorbidities.  Studies have shown that the prevalence of 
hypomagnesemia among diabetics range from 13.5 to 47.7% (4). Magnesium being the 
fourth most abundant cation in the body plays an important role in over 300 enzymatic 
reactions. Thus magnesium deficiency has been proposed as a possible contributor to 
diabetic complications (2). Of note is the large body of evidence that  shows a link 
between hypomagnesemia and reduction of tyrosine-kinase activity at the insulin receptor 
level, which may result in the impairment of insulin action and development of  insulin 
resistance (5, 6).  There is also evidence that magnesium supplementation may be 
associated with reduction in the incidence of diabetes and diabetic complications and co-
morbidities (7-9).  
      Although there are several studies in the literature both from the west and from India 
on the role of magnesium in diabetic complications, several aspects of association 
between the two are unclear (2). 
      This study was undertaken to assess the prevalence of hypomagnesemia in our 
diabetic  population, and to propose probable predictors for the same. 
 AIM 
 
To determine the prevalence and predictors of hypomagnesemia in the outpatient diabetic 
population at Christian Medical College Hospital, and to describe the association with 
diabetic complications and co-morbidities. 
 
 
 
 
OBJECTIVES 
 
1. To determine the prevalence of hypomagnesemia in type 2 diabetes mellitus. 
2. To ascertain if there was a correlation between hypomagnesemia and the presence 
of microvascular and macrovascular complications of type 2 diabetes mellitus. 
3. To correlate hypomagnesemia with comorbidities like hypertension and 
dyslipidemia.  
4. To evaluate the possible mechanisms of hypomagnesemia in diabetes in particular 
urinary magnesium excretion, drug history, dietary and drinking water 
magnesium content. 
 
 
 
LITERATURE REVIEW 
Introduction 
Diabetes mellitus is a group of metabolic disorders that share the phenotype of 
hyperglycemia. It results from defects in insulin secretion, insulin action or both (3, 10). 
Diabetes is one of the main threats to human health in the 21st century. Several 
epidemiological studies confirm that diabetes is one of the most common non-
communicable diseases globally, and is the fourth or fifth leading cause of death in most 
developed countries. 
      Diabetes can affect nearly every organ system in the body. It can cause blindness, 
lead to end stage renal disease, lower-extremity amputations and increase the risk for 
stroke, ischaemic heart disease, peripheral vascular disease, and neuropathy. 
Classification of Diabetes Mellitus 
The etiological classification of diabetes mellitus is as follows (Table:1)  (3):- 
Types Etiopathogenesis 
I. Type 1 diabetes Beta cell destruction, usually leading to absolute 
insulin deficiency 
a) Immune-mediated 
b) Idiopathic 
II. Type 2 diabetes      May range from predominantly insulin resistance to 
predominantly an insulin secretory defect 
III. Other specific types       a) Genetic defects in Beta Cell    
        Function/Insulin secretion 
      b) Genetic defects in Insulin Action 
      c)  Diseases of the Exocrine Pancreas 
d) Endocrinopathies 
e) Drug or Chemical Induced 
f) Infections 
g) Uncommon  Immune forms 
      h)  Genetic syndromes with diabetes  
IV. Gestational diabetes 
mellitus 
     Insulin resistance related to the metabolic changes of  
late pregnancy 
 
Epidemiology of Diabetes 
      The prevalence of diabetes ranges from nearly 0 per cent in New Guinea to 50 per 
cent among Pima Indians(11). The past two decades have seen an explosive increase in 
the number of people diagnosed with diabetes world-wide.  
 
World data: - The World Health Organization (WHO) estimated that there were 135 
million diabetics in 1995 and that this number would increase to 300 million by the year 
2025.   India is the first among the 10 countries where the prevalence is estimated to 
increase from 31.7 million in 2000 to 79.4 million by 2030 (12). 
  
Global diabetes prevalence by age and sex for 2000 (12). Borrowed from the Global prevalence of 
Diabetes. 
                            Figure 1: Estimates for the year 2000 and projections for 2030 
 
 Indian data: - India leads the world today with the largest number of diabetics in any 
given country. In the 1970s, the prevalence of diabetes among urban Indians was reported 
to be 2.1 per cent and this has now risen to 12.1 per cent (13). Moreover, there is an 
equally large pool of individuals with impaired glucose tolerance (IGT), many of whom 
will develop type 2 diabetes mellitus in the future (13).  
 
South Indian data: - The prevalence in the southern part of India is higher compared to 
other parts of India, as shown in the (graph 1) below: - 
Graph 1- Prevalence of diabetes in various parts of India 
 
The study also suggested that there was a large pool of subjects with IGT, 14% with a 
high risk of conversion to diabetes (NUDS study)(14). 
 
 
 
 
South India 
1.  Chennai- 13.5%  
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3. Hyderabad- 16.6% 
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      4.  New Delhi- 11.6% 
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      5.  Kolkatta- 11.7% 
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      6. Mumbai- 9.3% 
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
14.00%
16.00%
18.00%
Series1
Series1 13.50% 12.40% 16.60% 11.60% 11.70% 9.30%
1 2 3 4 5 6
Tamil Nadu data: - In a recent study published in 2008, it was found that the prevalence  
of diabetes in Chennai city was 18.6 %[16.6 –20.5]), compared to a nearby village, which 
had a prevalence of 9.2% [95% CI 8.0 –10.5], P< 0.0001 (1). 
Graph 2. The difference in the diabetes prevalence in Chennai city in the years 2000 
and 2006. 
 
 
Diagnosis of Diabetes Mellitus 
According to American Diabetes Association 2007, a diagnosis of Diabetes mellitus can 
be made, if the blood sugar values fulfill any one of the following criteria(10):-   
Criteria for the diagnosis of diabetes 
1. Symptoms of diabetes and a casual plasma glucose >/=200 mg/dl (11.1 mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of diabetes include polyuria, polydipsia, and unexplained 
weight loss. 
OR 
2. FPG >/=126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at 
least 8 h. 
OR 
3. 2-h plasma glucose >/=200 mg/dl (11.1 mmol/l) during an OGTT. The test 
should be performed as described by the World Health Organization, using a 
glucose load containing the equivalent of 75-g anhydrous glucose dissolved in 
water. 
 
This graph shows the difference in the 
diabetes prevalence in Chennai city in the 
years 2000 and 2006. 
The probable risk factors proposed were:- 
a) Increased urbanization 
b) Higher education 
c) Family history 
d) Age 
e) BMI/ waist circumference 
f) City > town > village life 
 
This graph borrowed from- Ambady Ramachandran etal. 
Diabetes Care, 2008. 31: p. 893-898. (1) 
Diagnosis of Impaired Fasting glucose 
Fasting glucose >100mg/dl and <126mg/dl
 
Diagnosis of Impaired glucose tolerance 
2 hours postprandial glucose >140mg/dl 
and <200mg/dl. 
 
The 75 gm OGTT is more sensitive, more specific than fasting plasma glucose in 
diabetes but is poorly reproducible and rarely performed in practice.  
Complications of Diabetes Mellitus  
        Diabetes mellitus causes both microvascular and macrovascular complications, as 
listed in Table 2. The microvascular complications include- neuropathy, nephropathy and  
retinopathy, whilst the macrovascular complications are ischemic heart disease, 
cerebrovascular disease and peripheral vascular disease(3). 
Table 2. Complications of diabetes mellitus: 
Microvascular Macrovascular Others 
•Retinopathy 
(nonproliferative or 
proliferative)  
 
•Neuropathy  
 
•Nephropathy  
 
•Cardiovascular disease  
 
•Peripheral vascular 
disease  
 
•Cerebrovascular 
disease  
 
GI  
• Gastroparesis  
• Diarrhea  
Genitourinary  
Lower extremity  
• Amputation  
•Foot ulcers and infections  
 
I. Neuropathy   
It is the commonest symptomatic complication of diabetes. It can be seen in 15-40% of 
the diabetic population from various studies. It can be classified as (15): 
- Subclinical neuropathy 
- Diffuse clinical neuropathy 
- Focal neuropathy 
- Mononeuropathy 
- Entrapment syndromes 
- Autonomic neuropathy 
Recognised methods (15):  
a) 10 g Semmes- Weinstein Monofilament for assessment of sense of touch 
b) 128 Hz tuning fork or biothesiometer- for testing vibration 
Impaired vibration sense is an early sign of neuropathy, hence its assessment is an 
important element of the neurological examination of the patient with diabetes. 
 
II.      Nephropathy 
Mogensen has classified diabetic nephropathy into several stages(15): 
1. Stage of glomerular hyper filtration and renal enlargement 
2. Early glomerular lesions or silent stage with normal albumin excretion 
3. Incipient nephropathy or the microalbuminuric stage 
4. Clinical or overt diabetic nephropathy: proteinuria and declining GFR 
      5.   End stage renal disease 
 
Microalbuminuria 
      Microalbuminuria is defined as 30- 299 microgms of albumin/ mg of  creatinine in a 
spot urine sample or 30-500 mg/day in a 24 hour urine collection (10). It can also occur 
with uncontrolled hypertension, fever, strenuous exercise, poor glycemic control or CCF. 
It may be seen 5 to 10 years after the onset of diabetes in 40% of type 1 diabetic patients. 
In clinical or overt nephropathy, macroalbuminuria is >300 microgms/ mg creatinine in 
the spot urine sample, or >500 mg/day in a 24 hour urine collection (3).  Endstage renal 
disease develops in 50% of type 1 diabetics with overt nephropathy within 10 years and 
in >75% by 20 years. Without specific interventions, 20 to 40 % of type 2 diabetics with 
microalbuminuria progress to overt nephropathy, but by 20 years after onset of overt 
nephropathy, only about 20% will have progressed to ESRD (3). Albuminuria is a marker 
of greatly increased cardiovascular morbidity and mortality for diabetic patients (3).  
 
III. Retinopathy 
           It was found that diabetics are 25 times more likely to become legally blind than 
non diabetics (3).  Diabetic retinopathy is characterized by microaneurysms, blot 
hemorrhages and cotton wool spots, and based on this is classified into non-proliferative 
and proliferative. Non-proliferative retinopathy is seen in about 25% of diabetics in 5 
years and in 80% after 15 years among type 1 diabetics and in about 39% in type 2 
diabetics (3).  
 
 IV. Coronary artery disease 
        Coronary artery disease is 3 times more common in diabetics. The usual 
manifestations include angina, acute myocardial infarction, post MI failure, 
dysrhythmias, complications like shock, conduction disturbances, cardiac failure, re-
infarction and ketoacidosis. Other manifestations included are atypical ischemic 
symptoms like dyspnoea, hypotension, sweating and syncope etc (3). 
 
 
 
V. Cerebrovascular disease: 
       Diabetics have also a higher incidence of cerebrovascular disease in the form of  
transient ischemic attack, stroke, carotid stenosis etc. The risk of stroke is at least three 
fold higher in diabetics than in nondiabetics (3). 
 
 
VI. Peripheral vascular disease: - 
         It is clinically identified by a history of intermittent claudication and absent 
peripheral pulses in the extremities. With the use of doppler technology and blood 
pressure measurements of the extremity, it can be recognised noninvasively before 
clinical manifestations although angiography remains the gold standard. It is more than 
twice as common in the diabetic population as in the nondiabetic group, as evidenced 
from the ARIC and UKPDS studies (3). 
 
 
 
 
 
 
 
 
 
Hypomagnesemia in Diabetes mellitus 
Introduction 
        Magnesium has been proposed to play a role in the pathogenesis of diabetes and its 
complications. 
          To date, only obesity and physical inactivity have been well established as 
modifiable risk factors for type 2 diabetes. Magnesium deficiency has been emerging as a 
novel risk factor, which could be modifiable. 
          Magnesium (Mg2+) is the second most abundant intracellular cation after 
potassium and the fourth most abundant cation of the body after calcium, potassium, and 
sodium. It has a molecular weight of 24.3 and the valence is +2, and 1 meq/L is 
equivalent to 0.50 mmol/L or 1.2 mg/dL. The normal range of plasma magnesium 
concentration is 1.7-2.4 mg/dl (0.7-1.0 mmol/l), and is maintained remarkably constant 
(3). 
Biochemistry of Magnesium 
          Mg2+ is an important co-factor for many biologic processes, most of which use 
ATP. It is an essential mineral that is important for bone mineralization, muscular 
relaxation, neurotransmission and other cell functions. Most of the intracellular 
magnesium is located within the mitochondria apparently because magnesium binds 
strongly with ATP. In general, the more metabolically active the cell is, the higher is its 
magnesium content (16). Extracellular Mg2+ concentration is tightly regulated by the 
extent of intestinal absorption and renal excretion. 
 
 
Body stores of magnesium 
          Dietary Mg content normally ranges from 140 to 360 mg/day (3) and the total body 
Mg2+ concentration is approximately 2000 mEq, or 25 g.  The distribution of Mg2+ in      
the body is as follows: 
1. Bone- about 60% 
2. Muscle-20% 
3. Other tissues- 20% 
    4. Only a small fraction-1% is in the 
extracellular fluid compartment. Because 
serum Mg is only <1% of total body Mg, 
measurements of serum Mg levels may not 
accurately reflect the levels of body stores of Mg (3, 17).                
         Magnesium homeostasis depends on the balance between intestinal absorption and 
renal excretion. Within physiological ranges, diminished magnesium intake is balanced 
by enhanced magnesium absorption in the intestine and reduced renal excretion. These 
transport processes are regulated by metabolic and hormonal influences, but these 
influences are  not as significant as in calcium homeostasis (17) 
 
Absorption and regulation of magnesium 
A) Gastrointestinal Metabolism: 
        The principal site of magnesium absorption is the small intestine, with smaller 
amounts being absorbed in the colon. 25 to 60% of dietary Mg is absorbed in the 
gastrointestinal tract (2). 
Distribution of Mg in different tissues in the 
body
Other 
tissues, 
20%
Muscle, 
20%
Bone 59%
Extra
cellular 
f luid 1%
1
2
3
4
Intestinal magnesium absorption occurs via two different pathways (2): 
1. A paracellular simple diffusion (passive transport) at high intraluminal 
concentrations.   
2. A saturable active transcellular transport which involves Mg specific transporters, 
esp, TRPM6 (Transient receptor potential channel melastatin 6) along the brush 
border membrane of the small intestine at low intraluminal concentrations. 
 
B) Renal Metabolism (Figure 2): 
1. Glomerular filtration:  In the kidney, 80% of total serum magnesium is filtered in the 
glomeruli with 95% being reabsorbed along the nephron (2).  
2. Proximal tubules: 15–20% is reabsorbed in the proximal tubule.  
3. Loop of Henle: 70% is reabsorbed in the loop of Henle, especially in the cortical thick 
ascending limb (TAL).   
4. Distal convoluted tubules: Only 5–10% of the filtered magnesium is reabsorbed in the 
distal convoluted tubule (DCT). It determines the final urinary magnesium excretion. 
5. Finally, 3–5% of the filtered magnesium is excreted in the urine..   
 
 
 
 
 
 
 
(Figure2: Borrowed from Clin. J.Am.Soc. Nephrol. 
2007 by Pham etal (2) 
Renal Mg handling- After glomerular filtration, 
ionized Mg is reabsorbed passively in parallel to 
sodium reabsorption in the proximal tubules (PT); 
paracellularly via claudin 6 (CLD16; paracellin 1) at 
the thick ascending limb of the loop of Henle (TAH); 
and transcellularly via transient receptor potential 
channel melastatin (TRPM6) at the distal convoluted 
tubule (DCT); and  CT- collecting tubules.) 
 
Epidemiology of hypomagnesemia 
1. Prevalence of hypomagnesemia in the general population:  
        Estimates of prevalence in the general population ranges from 2.5% to 15% in 
different studies (18). There are certain factors that are associated with a higher risk for 
hypomagnesemia:  
a) elderly 
b) people in nursing/ old age homes 
c) hospitalized patients 
d) decreased dietary intake- refined foods, acid rain 
e) decreased drinking water content of magnesium 
 
2. Prevalence of hypomagnesemia in the hospital population: 
       Hypomagnesemia is a common entity occurring in about 7 to 12% of hospitalized 
patients (16, 19). The factors for the high prevalence of hypomagnesemia in hospitalized 
patients could be   
 Magnesium free parenteral fluids 
 Prolonged nasogastric suction 
 Infectious diarrhea 
 Steatorrhoea 
 Inflammatory bowel disease  
 GI neoplasms. 
 Drugs- diuretics 
 Alcohol dependence- Incidence of hypomagnesemia among people with 
alcohol dependence is approximately 25% and mainly is due to magnesium 
diuresis caused by alcohol.  
 Intensive care setting 
3. Prevalence of hypomagnesemia in the Intensive care unit (ICU) population 
        Hypomagnesemia is extremely common in patients in ICU (20, 21) and the 
incidence rises to as high as 60 to 65% in patients in this setting. In one study 
hypomagnesemia on admission to the intensive-care unit was associated with a mortality 
rate approximately twice that of comparably ill normomagnesemic patients (22, 23). It 
has not been shown however, that treatment with magnesium supplementation would 
improve the outcome. Most of the ICU’s are now supplementing Mg for their patients on 
a routine basis.  
4. Prevalence of Hypomagnesemia among Patients with Type 2 Diabetes 
            Hypomagnesemia has been reported to occur in 13.5 to 47.7% of nonhospitalized 
patients with type 2 diabetes compared with 2.5 to 15% among their counterparts without 
diabetes (24-29). Magnesium has been associated with the cause and consequence of 
diabetes and its complications. There are many studies around the world, and a few from 
India, which have looked at the prevalence of diabetes in hypomagnesemic individuals. 
There are also studies which looked at correlation of diabetic complications with 
hypomagnesemia. Mg has also been implicated in the negative correlation between 
cardiovascular disease and hardness of drinking water. In terms of gender difference, it is 
interesting to note that independent studies have reported a higher incidence of 
hypomagnesemia in women compared with men, at a 2-to-1 ratio (25, 30). 
a) Prevalence studies from the west:- 
       There are many studies from the west which have shown a high prevalence of 
hypomagnesemia in diabetic populations, as given in table 3. Some of  the studies have 
compared mean Mg levels between IDDM and NIDDM for eg. by Garber (31). 
Chambers found a lower mean Mg concentration among the diabetics than in the 
nondiabetics, 1.92 ± 0.16 mg/dl in diabetics vs. 2.01 +/- 0.16 mg/dl in nondiabetics (p 
<0.001) as shown in table 3 (32).  
         Table 3: Hypomagnesemia- Studies on prevalence and mean Mg 
concentrations from abroad: 
Study name, 
place and 
journal 
published 
(reference) 
Number of diabetics 
included 
Mean magnesium 
value 
Prevalence 
of 
hypomagne
semia 
Relevant 
features  
Garber etal, 
United states 
Clin Ther 1996 
(31) 
199 diabetics, who 
had never been on 
Mg supplementation 
1.48mg/dL in 
IDDM, and  was 
1.44mg/dL in 
NIDDM 
78.3% No correlation 
was found 
between HbA1c 
and serum Mg 
levels 
Rodriguez-
moran etal 
Mexico 
Diabetes Care 
2003 (33) 
63 diabetics 1.56 +/- 0.16 mg/dl NA Serum Mg 
inversely 
correlated with 
HbA1c values 
Chambers etal 
New York 
J.Am.col Nut 
2006 (32) 
485 diabetics 1.92 ± 0.16 mg/dl 
vs. 2.01 +/- 0.16 
mg/dl in 
nondiabetics 
(p <0.001) 
NA Strongly 
correlated 
diabetes and 
hypomagnesemia 
Schnack etal 
Germany 
Diabetologia 
1992 (34) 
50 diabetics 1.89 +/- 0.02 mg/dl 
in DM vs 2.11 +/- 
0.02 mg/dl in 
normal controls (p 
less than 0.0001). 
NA Serum Mg levels 
were low inspite 
of strict metabolic 
control over 3 
months 
Levin  etal 
Germany 
Diabetologia 
1981 (35) 
17 diabetics and 17 
normal 
1.92 +/- 0.04 mg/dl 
in diabetics vs. 2.16 
+/- 0.04 mg/dl in 
normals (p < 0.001) 
NA Intracellular Mg 
content was not 
different between 
the cases and 
controls 
Khan etal 
Bangladesh 
Am J Clin Nut 
1999 (36) 
40 which included 
type 2 diabetes (I), 
Fibrocalculous 
diabetes mellitus (II) 
and protein deficient 
diabetes (III) 
1.68+/-0.19 mg/dl 
in I, 1.58+/-0.16 
mg/dl in II and 
1.63+/-0.14 mg/dl 
in III 
 
42.85% in I, 
69.23% in II 
and 61.54% 
in III  
Significantly 
lower Mg levels 
in the diabetics 
compared to 
normal controls 
b) Studies from India showing prevalence of hypomagnesemia and mean Mg 
concentration in diabetics- 
         There are also a few studies from India- mainly from the north india, which have 
shown a higher prevalence of hypomagnesemia in the diabetics and also a lower mean 
Mg concentration in the diabetics than nondiabetics. Table 4 gives a summary of the 
studies published from the north India with regard to the same. 
 
Table 4: Hypomagnesemia - Studies from India: 
Study name, 
place and 
journal 
published 
(reference) 
Number 
of 
diabetics 
included 
Mean magnesium 
value 
Preval
ence 
of 
hypo
magne
semia 
Relevant features 
Sharma 
Bikaner 
JIMA 2007 
(37) 
50 
diabetics 
and 40 
normals 
1.93 +/- 0.282 meq/l in 
diabetics and 2.25 +/- 
0.429 meq/l in controls 
(p<0.005) 
NA Strong association 
between 
hypomagnesaemia and 
retinopathy, obesity 
and hypertension 
 
Hans 
Chandigarh 
Int J Diab Dev 
Ctries 2002 
(38) 
100 
diabetics 
1.81 +/- 0.12 mg/dl in 
diabetics 
Compared to  
2.06+/-0.068 mg/dl in 
normals (p<0.02) 
25% Strong correlation 
between serum and 
RBC Mg, also with 
oxidative stress 
J Lal  
New Delhi 
JAPI  2003 
(39) 
40 
diabetics 
and 54 
controls 
1.44 +/- 0.48 mg/dl in 
cases 
Compared to 
2.29 +/- 0.33mg/dl in 
controls (p<0.001) 
NA Supplemenattion 
showed improvement 
in lipid profile, but no 
significant effect on 
blood glucose levels 
 
 
 
 
 
 
 
 
Hypomagnesemia and diabetic complications 
           There are also a few studies which have shown a positive correlation between 
hypomagnesemia and diabetic complications like cardiovascular disease (28), diabetic 
foot ulcers (7), retinopathy and neuropathy. 
 Coronary artery disease- Hypomagnesemia has been for a long time associated 
with development of atherosclerosis and coronary artery disease. There are many follow 
up studies which have shown an association between the two including ARIC cohorts as 
published by Jing Ma etal and Liao etal. (The Atherosclerosis Risk in Communities -
ARIC) Study, a multicenter, prospective cohort study that lasted 4 to 7 yr and involved 
13,922 middle-aged adults who were free of coronary heart disease at baseline- found an 
inverse association between serum Mg and the risk for coronary heart disease in men 
with diabetes (28, 40)).  
          Magnesium depletion can induce changes in the electrocardiogram- widening of 
the QRS complex and peaking of T waves have been described with modest magnesium 
loss, while more severe magnesium depletion can lead to prolongation of the PR interval, 
progressive widening of the QRS complex, and diminution of the T wave (24, 41).   
          The clinical disturbance of greatest potential importance, however, is the 
association of mild hypomagnesemia with ventricular arrhythmias in patients with 
cardiac disease. A number of uncontrolled studies suggest that hypomagnesemia may be 
an important risk factor for arrhythmias in the setting of an acute ischemic event, 
congestive heart failure, torsades de pointes, after cardiopulmonary bypass, or in the 
acutely ill patient in the intensive care unit. 
          The mechanism underlying a possible association between hypomagnesemia and 
arrhythmias is at present unknown. Arrhythmias could be due to concurrent hypokalemia, 
hypomagnesemia itself, or both. Magnesium regulates several cardiac ion channels, 
including the calcium channel and outward potassium currents through the delayed 
rectifier (42).         
 Diabetic Retinopathy- The link between hypomagnesemia and diabetic 
retinopathy was also supported by multiple studies, and not only did patients with 
diabetes have lower serum Mg levels compared with their counterparts without diabetes, 
but also the serum Mg levels among the cohort with diabetes had an inverse correlation 
with the degree of retinopathy (43). Mc Nair etal reported that diabetes induced damage 
to the eyes is more likely to occur in magnesium deficient patients with insulin dependent 
diabetes mellitus (44). A similar link, however, was not observed when Mg was 
measured within mononuclear cells.  
 Foot Ulcerations- Given the link between hypomagnesemia and risk factors for 
the development of diabetic foot ulcers (e.g., polyneuropathy, platelet dysfunction), 
Rodriguez- Moran and Guerrero-Romero (7) suggested that hypomagnesemia may be 
associated with an increased risk of diabetic foot ulcers, as elucidated in table 5 below. 
Indeed, they observed a higher incidence of hypomagnesemia among their patients with 
diabetic foot ulcers compared with those without the condition and also a lower mean Mg 
concentration among the foot ulcer patients, than those without. 
 Nephropathy- Hypomagnesemia has also been associated with microalbuminuria 
and nephropathy. It is a controversy, as to whether the hypomagnesemia could be in fact 
secondary to hypermagnesuria in nephropathy or whether hypomagnesemia is anyway 
linked to advanced diabetes with complicatins. Corsonello etal conducted a  comparative 
study that involved 30 patients who had type 2 diabetes without microalbuminuria, 30 
with microalbuminuria, and 30 with overt proteinuria, and observed a significant 
decrease in serum ionized Mg in both the microalbuminuria and overt proteinuria groups 
compared with the nonmicroalbuminuric group as shown in table 5 (45). According to a 
study done by Pham etal, there was a strong association between the low levels of serum 
magnesium and a faster rate of renal dysfunction among type 2 diabetics. Patients 
belonging to lower Mg groups for both genders had significantly worse slopes when 
plotted against renal parameters and that association was independent of the presence of 
hypertension and use of ACEI/ARB, diuretics, HMG-CoA enzyme inhibitors or aspirin 
(25). 
 Others- Dyslipidemia and hypertension- Finally, there also are data to suggest the 
association between hypomagnesemia and other diabetic co-morbidities like dylipidemia 
(46) and hypertension (28), also showing improvement after supplementation (47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Hypomagnesemia- Correlation with dibetic complications and co-
morbidities 
 
Study 
name, 
place and 
journal 
published 
(reference
) 
Number of diabetics 
included 
Mean magnesium value Prevalence 
of 
hypomagne
semia 
Relevant features 
Rodriguez
-moran 
etal 
Mexico 
Arch Med 
Res. 2001 
(7) 
33 diabetics with foot 
ulcers (cases) vs. 66 
diabetics without foot 
ulcers (controls) 
 
1.48 +/- 0.33 mg/dl in 
cases vs. 1.68 +/- 0.32 
mg/dl in controls 
(p<0.001) 
93.9% in 
cases vs. 
73.1% in 
controls 
(p=0.02) 
Hypomagnesmia 
had strong 
correlation with 
foot ulcers , odds 
ratio 2.9 
Corsonell
o etal 
Italy 
Am J 
Nephrol 
(45) 
30 diabetics with 
normoalbuminuria(I) 
30with 
microalbuminuria (II) 
and 30 with clinical 
proteinuria (III) 
Serum ionized Mg 
levels- 1.08+/-0.04 mg/dl 
in group I; 0.86 +/- 0.12 
mg/dl in group II;  0.84 
+/- 0.09 mg/dl, p < 0.001 
NA Serum ionized Mg 
levels seems to 
positively correlate 
with stages of 
diabetic 
nephropathy 
Lima etal, 
Brazil 
Diabetes 
care 
1998 (29) 
128 diabetics 1.77+/-0.41 mg/dll 47.7% total 
serum Mg, 
31.1% had 
low 
intramononu
clear levels 
Positively 
correlated with 
peripheral 
neuropathy and 
CAD 
 
Evidence for benefit from supplementation 
         A few studies had shown benefit from replacement of magnesium in various aspects 
(Table 6), including improvement in co-morbidities- dyslipidemia and hypertension. 
Most of the intervention trials have been done on small populations of diabetics.  The 
duration for supplementation has also been of the range of few weeks to months, and 
there is lack of evidence for benefit from long term supplementation. In the trials, both 
high concentration Mg solutions and Mg tablets have been used for supplementation.    
 
Table 6: Studies - Benefit from Mg supplementation 
Study 
name and 
journal 
published 
Numbe
r of 
diabetic
s 
include
d 
Compound used Dura
tion 
of 
treat
ment 
Change in serum 
magnesium 
Outcomes 
Yokota 
etal, 
Japan  
Journal of 
the 
American 
Coll of 
Nutr 
2004 (48) 
9 MAG21, 
viscous acidic 
water with MG 
content 71mg/dl 
30 
days 
2.1 +/- 0.06 mg/dl 
to 2.3 +/- 0.07 
mg/dl 
a)Systolic BP- 136.3+/-
2.68 to 130.8+/-2.79 
b) DBP -83.0+/-5.14 to 
79+/-5.86 
c)Triglycerides from 
255.4+/-80.5 to 
178.8+/-38.3 
Rodrigue
z Moran 
etal 
Mexico 
Diabetes 
care,  
2003 (33) 
63 50 ml MgCl2 
solution and 
placebo 
16 
wee
ks 
1.56+/-0.17 mg/dl 
vs 1.77+/-0.24 
mg/dl in controls 
a) HbA1c 8.0+/-2.4 vs. 
 10.1+/-3.3% in the 
controls 
b) Total cholesterol 
6.4+/-1.9 vs. 7.0+/-1.7 
deValk 
etal, 
Netherlan
ds 
Diabet 
Med 
1998 (49) 
50 15 mmol of Mg 
vs placebo 
3 
mont
hs 
Plasma Mg after 
supplementation 
(1.96 +/- 0.17mg/dl 
in cases vs 1.87 +/- 
0.19 mg/dl, p < 
0.05), in placebo 
Increase in urinary Mg 
excretion, no change in 
glycemic control or 
lipid concentration 
Eibl etal 
United 
States 
Diabetes 
care 
1995(50) 
40 30 mmol of oral 
Mg/day 
3 
mont
hs 
Mg: 1.75 +/- 0.19 
mg/dl 
baseline vs. 1.94 +/- 
0.02 mg/dl after 
supplementation 
2.11 +/- 0.19 mg/dl  
in controls (p-NS) 
Metabolic control was 
not altered 
J Lal etal, 
Delhi  
JAPI 
2003 (39) 
40 600 mg of MgO 
once a day 
12 
wee
ks 
1.44 +/- 0.48 mg/dl 
to 2.17 +/- 0.26 
mg/dl 
a)Triglycerides from 
189.3+/-93.8 to 
153.8+/-53.5 
b)LDL from 124.1+/-
53.3 to 76.1+/-27.3 
c)Diastolic BP from 
76.55+/-8.66 to 71.1+/-
6.93 mm of Hg 
 
Hypomagnesemia – Possible mechanisms in the pathogenesis of diabetes and 
diabetic complications  
       There is considerable evidence to suggest that hypomagnesemia may adversely affect 
various aspects of cellular physiology. Insulin regulates the intracellular magnesium 
concentration by stimulating the plasma membrane ATPase pump (51). 
1) Insulin resistance- A study to explore link between magnesium deficiency and insulin 
resistance, looked at the effect of diet lacking in magnesium on insulin resistance in non 
diabetics (52). Diet induced magnesium deficiency leads to decreased insulin sensitivity 
in lean non-diabetics (53). It was also shown that oral magnesium supplementation 
improves insulin sensitivity in hypomagnesemic non-diabetic subjects (6). 
2) Accelerated atherosclerosis- Hypomagnesemia has been proposed to accelerate 
atherosclerosis via the following mechanisms:    
a) Endothelial dysfunction and thrombogenesis- It may promote endothelial cell 
dysfunction and thrombogenesis via increased platelet aggregation and vascular 
calcifications (35, 54, 55). It causes collagen and ADP induced platelet aggregability,  by 
increasing the pro-aggregating effect of leptin (38, 56). 
b)  Reduction in plasma antioxidant levels 
- Plasma levels of malondialdehyde have been found to be increased in the diabetic 
patients with hypomagnesemia, associated with significant reduction in the levels of 
plasma antioxidants (38).  
-Magnesium deficiency may be involved in the initiation and propagation of free radical 
myocardial tissue damage through oxidation of myoglobin, which is essential for 
intracellular transport and storage of oxygen (17, 39, 57).  
- Hypomagnesemia causes decreased ascorbic acid levels.  
- Magnesium is an obligatory cofactor in the enzyme reaction of GSH synthesis and so 
magnesium deficiency has been reported to inhibit the biosynthesis of GSH (58, 59) 
c) Proinflammatory and Profibrogenic response- It may lead to the induction of 
proinflammatory and profibrogenic response (36-38, 60). 
d) Induction of vasoconstriction and hypertension- By elevation in smooth muscle and 
cardiac intracellular calcium concentration (61). It has been observed that after Mg 
supplementation, there is increase in intracellular Mg and decrease in intracellular 
sodium, thus lowering blood pressure through the suppression of adrenergic tone and 
possible natriuresis, because Mg supplementation increases urinary noradrenaline 
excretion (62).  
e) Reduction of inositol transport- A reduction in the rate of inositol transport, and 
subsequent intracellular depletion was also linked to the development of complications 
(63). 
f) Increase in urinary thromboxane concentration – It was observed that the urinary 
thromboxane concentration increased after magnesium deficiency, pointing towards 
hypomagnesemia as a common factor in insulin resistance and vascular disease (53).  
 
 
 
 
 
 
Causes of hypomagnesemia 
        It has been observed that refining and processing of food causes a substantial loss of 
magnesium. For example, the refining and processing of wheat to flour, rice to polished 
rice and corn to starch depletes magnesium by 82, 83 and 97% respectively. Thus a 
western lifestyle and processing partially explains why a significant segment of the 
population has intake of magnesium below recommended dietary amounts and may be 
predisposed to chronic, latent magnesium deficiency (64).  
        The western diet is characterized by a high intake of saturated and trans fats and 
refined grains and low intake of whole grains, vegetables and fiber, resulting in low 
micronutrient intake(65).  
        There are other factors which have reduced magnesium within the ecosystem as a 
whole. Acid rain causes exchange between magnesium and aluminium in the soil. This 
coupled with intensive farming of the soil, has led to a reduction in magnesium within the 
food chain (1).   
         The contribution of drinking water magnesium to overall magnesium intake is 
generally about 10% (66). It has been argued that bioavailability of magnesium is greater 
from water than from food, and there are studies which have shown that upto 40-50% of 
waterborne magnesium may be absorbed compared to about 30% from food (67). Thus 
waterborne magnesium would have relative importance, particularly in patients whose 
diets are relatively deficient in magnesium.  The usual causes for hypomagnesemia are 
given in table 7. 
 
 
Table 7: Causes of hypomagnesemia (3, 68):- 
a) Poor Magnesium intake 
- Starvation 
- Anorexia 
- Protein calorie malnutrition 
- No Mg in intravenous fluids 
 
b) Gastrointestinal losses 
- Nasogastric suction 
- Vomiting 
- Intestinal bypass for obesity 
- Short bowel syndrome 
- Inflammatory bowel disease 
- Pancreatitis 
- Diarrhea 
- Laxative abuse 
- Villous adenoma 
            -Primary infantile hypomagnesemia 
c) Renal losses 
- Acute renal failure- diuretic 
 phase of acute tubular necrosis 
- Renal tubular acidosis 
- Post obstructive diuresis 
- Primary renal tubular  
magnesium wasting 
- Bartter syndrome 
- Gitelman syndrome 
 
d) Drugs 
- Diuretics- Acetazolamide, 
 thiazides, furosemide 
- Alcohol 
- Antibiotics-Aminoglycosides, 
Carbenicillin 
- Cisplatin 
- Digoxin 
- Ethacrynic acid 
- Foscarnet 
- Mannitol 
- Methotrexate 
- Pentamidine  
- Tacrolimus 
e) Endocrine disorders 
- Hyperaldosteronism 
- Hyperparathyroidism 
- Hyperthyroidism 
- Diabetes mellitus 
- Hypoparathyroidism 
- Syndrome of Inappropriate  
secretion of Anti diuretic hormone 
f) Other causes 
- Alcohol withdrawal 
- Extensive Burns 
- Exchange transfusions  
(redistribution) 
- Lactation 
- Acute pancreatitis  
(redistribution) 
 
 
 
 
 
 
Possible causes of hypomagnesemia in diabetes 
The following are the possible explanations for the higher prevalence of 
hypomagnesemia in diabetics (2), as modified from Pham etal, in Clin J Am Soc 
Nephrol: -  
1. Dietary deficiency – The major sources of magnesium in the food supply are dairy 
products (20%), grain products (20%), meat, poultry and fish (15%), legumes, nuts and 
soya products (13%)- most of these have been restricted in a diet prescribed for diabetics, 
which could be contributing to the higher prevalence of hypomagnesemia in diabetics 
(28).  
2. Decreased intake – secondary to diabetic autonomic neuropathies, which may 
reduceintake and absorption- (69): 
        -poor oral intake 
        -esophageal dysfunction 
        -diabetic gastroparesis 
3. Enhanced gastrointestinal loss 
        -diarrhea as a result of autonomic dysfunction 
4. Enhanced renal magnesium loss 
      -enhanced filtered load by glomerular hyperfiltration 
      -osmotic diuresis (glucosuria) 
      -metabolic acidosis (diabetic ketoacidosis)- by increasing the serum ionised Mg 
fraction (70) 
      -hypoalbuminemia- by increasing the serum ionised Mg fraction (70)  
      -microalbuminuria and overt proteinuria- as a result of protein bound magnesium loss 
(45) 
5. Enhanced tubular flow 
        -volume expansion as a result of excessive volume replacement- induce renal Mg 
wasting and may reduce tubular reabsorption due to high tubular flow (70). 
6. Reduced renal reabsorption 
        -endocrinologic dysfunction: insulin deficiency or resistance, causing decreased Mg 
reabsorption at the TAL (71) 
        -metabolic acidosis (diabetic ketoacidosis) 
        -diuretics (2) 
         
Clinical manifestations of hypomagnesemia 
Hypomagnesemia may cause generalized alterations in neuromuscular functions as 
described in the following table 8 (3). They are usually aymptomatic when serum Mg 
levels are greater than 1.2 mg/dl. 
Table 8: Manifestations of hypomagnesemia 
 
a)Electrolyte 
abnormalities 
           hypokalemia 
           hypocalcemia 
 
b)Neuromuscular 
 
         carpopedal spasm 
         tetany 
         muscle cramps 
         fasciculations 
         weakness 
         tremulousness 
         hyperactive reflexes
         myoclonus 
c) Cardiovascular 
 
         ventricular      arrhythmias 
         torsade de points 
         supraventricular tachycardia 
         enhanced sensitivity to digoxin 
         angina pectoris 
         congestive heart failure 
         atherogenesis 
 
 
d) Neurologic 
         vertigo 
         ataxia 
         nystagmus 
         aphasia 
         hemiparesis 
         depression 
         psychosis 
         delirium 
         choreoathetosis 
 
 e) Skeletal 
   Osteoporosis 
   Osteomalacia 
 
 
 
Diagnosis of Hypomagnesemia 
        Hypomagnesemia is diagnosed when the serum level of magnesium value is less 
than or equal to 1.7 mg/dl or less than 0.7 mmol/l or <2 SD below the mean of the 
general population (3). 
         Traditionally, hypomagnesemia refers to a low serum magnesium (Mg) 
concentration because this measurement has long been readily available. However, 
because Mg is mostly an intracellular cation, it has been questioned whether one can use 
measurements of serum Mg concentrations to study the impact of Mg on various 
physiologic conditions. Some investigators, instead, have used measurements of 
intracellular Mg concentrations, which is usually estimated using NMR (Nuclear 
magnetic Resonance) spectroscopy. The usual cells where the intracellular levels are 
measured are- erythrocytes or lymphocytes (72).  Some studies have been done on 
muscle and brain- and it has been measured non-invasively by NMR spectroscopy. 
Clinically, it has been suggested that in a patient with suspected Mg deficiency, a low 
serum Mg concentration is sufficient to confirm the diagnosis. However, if the serum Mg 
level is normal in this patient, then other more sensitive tests – intracellular (54, 73) and 
ionized levels should be performed. Although controversies still exist as to how 
hypomagnesemia could be best gauged, most of the studies so far have relied 
predominantly on the measurement of serum Mg concentrations. There are a few studies 
done using serum ionised magnesium concentration (the cut off is 0.46 mmol/l or 1.1 
mg/dl) which also showed significantly lower levels of serum ionized Mg in diabetics 
(45, 74, 75). 
             The diagnosis can usually be obtained from the history, as magnesium depletion 
is a result of either gastrointestinal or renal losses, often promoted by drugs. In less 
obvious cases, the distinction between gastrointestinal and renal losses can be made by  
determination of the fractional excretion of magnesium or the measurement of the 
magnesium excretion in the 24-hour urine sample (68). The fractional excretion is 
calculated as follows 
  
 
 
(U and P refer to the urine and plasma concentrations of magnesium (Mg) and creatinine (Cr). About 70% 
of PMg are not bound to albumin and therefore, filtered across the glomerulus (0.7 X PMg)) 
 
Fractional excretion above 2% in a subject with normal renal function indicates renal 
magnesium wasting (68). The reference range of 24 hour urine magnesium is 3-5 mmol/l, 
ie equivalent to 70- 120 mg/l (76) . 
FE. Mg = U.Mg X P. Cr              X 100 
                (0.7 X P.Mg) X U.Cr 
 Treatment of hypomagnesemia                                                             
The route of magnesium repletion depends on the severity of clinical manifestations. In 
cases of severe (<1.2mg/dl in the serum) and symptomatic hypomagnesemia with 
neuromuscular or neurologic manifestations or cardiac arrhythmias, Mg repletion should 
be achieved by intravenous administration of 2 g of Magnesium sulphate in 100 ml of 5% 
dextrose over 5 to 10 min and followed by a continuous infusion of 4 to 6 g/d for 3 to 5 d 
if renal function is relatively normal. The indication for parenteral administration is 
symptomatic hypomagnesaemia with tetany or severe ventricular arrhythmia (68). The 
underlying disease should be treated, if possible.  
  Correcting the hypomagnesemia, especially by intravenous application, will 
partially remove the stimulus to magnesium retention in the kidney as the plasma 
magnesium concentration is the major regulator of active magnesium resorption in the 
loop of Henle. Thus, oral supplementation is preferred in symptom-free patients (5– 20 
mmol/day in divided doses as magnesium chloride or lactate). However, diarrhea may 
become a dose-limiting side-effect. Maintenance therapy may require oral administration 
of Mg oxide (400 mg twice daily or three times daily) for as long as the risk factors for 
Mg deficiency exist. Oral Mg gluconate (500 mg twice daily or three times daily) can 
also be used (77). 
 
 
 
 
 
Hypomagnesemia and other electrolyte abnormalities 
Associated hypokalemia 
Hypokalemia is a common event in hypomagnesemic patients, occurring in 40 to 60% of 
cases (78). This relationship is in part due to underlying disorders that cause both 
magnesium and potassium loss, such as diuretic therapy and diarrhea. Potassium 
secretion from the cell into the lumen in the cells of the thick ascending limb and cortical 
collecting tubule is mediated by ATP-inhibitable luminal potassium channels (79). 
Hypomagnesemia is associated with a reduction in cell magnesium concentration, which 
may then lead to a decline in ATP activity, and, due to removal of ATP inhibition, 
an increase in the number of open potassium channels (79). 
 
 
 
Associated Hypocalcemia 
The most classical sign of severe hypomagnesemia <1.2 mg/dl is hypocalcemia.  
A reduction in extracellular magnesium concentration stimulates the secretion of 
parathyroid hormone (PTH) in the absence of changes in calcium concentration (80, 81).  
The adenylate cyclase systems of various organs may be affected differentially by a state 
of magnesium deficiency. It is suggested that magnesium deficiency may result in 
defective cyclic AMP generation in the parathyroid glands and in the PTH target organs. 
This could be the principal mechanism operative in both impaired PTH secretion and 
end-organ resistance to PTH which together contribute to the development of 
hypocalcaemia (81). 
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METHODOLOGY 
 
Setting                 The study was conducted among the patients presenting to the diabetic 
outpatient clinic run by the Department of Endocrinology of the Christian Medical 
College (CMC), Vellore, South India, which is a 2200 bedded tertiary care teaching 
hospital. 
 
Duration of Study          
May 2007 to May 2008. 
 
Inclusion Criteria 
1. Diabetic patients who were ambulant and willing to complete a 24 hour urine and 
serum sample were included  after informed consent. 
2. Diabetics who were willing to follow up in future in the same outpatient clinic- 
belonging to areas within a 50 km radius from the main hospital  
 
Exclusion Criteria 
1. The patients who had not completed the investigations – serum magnesium and 
24 hours urine magnesium.  
2. Diabetics who were not willing to follow up in the same out patient clinic 
 
 
 
Study Design 
The study was a cross-sectional descriptive study on diabetic patients attending the 
endocrine diabetic clinic in our centre. 
 
Sample size 
With an expected incidence of 25% and absolute precision of 10 % with an alpha error of 
5%, the desired sample size calculated was 80. 
 
Study Protocol 
        All local patients who were diagnosed to have diabetes mellitus, and were attending 
the diabetic endocrine clinic were interviewed. The patients who fulfilled the inclusion 
criteria, and were willing to participate in the study, were enrolled into the study. Upon 
enrollement into the study, complete demographic details, relevant clinical and laboratory 
parameters were collected. The details including duration of diabetes, drug history and 
parameters for comorbidities were also collected. 
 The following specific data was collected through a proforma (Annexure A) at the time 
of enrollment into the study 
1. Demography- Age, Sex, Region, Marital status, Phone number 
2. Evaluation of stage of diabetes- duration 
3. Vital parameters- blood pressure, body mass index 
4. Clinical evaluation of diabetes- including evaluation for 
hypertension, retinopathy, neuropathy by monofilament and 
biothesiometer, peripheral vascular disease by absent pulses, 
carotid and renal artery stenosis- by bruit. 
5. Laboratory parameters- regarding glycemic control by HbA1c, 
lipid profile- Total, LDL and HDL cholesterol, evaluation for 
nephropathy by urine microalbumin/ 24 hour urine protein/ 
serum creatinine. 
6. Drug history – Details of treatment for diabetes- including 
sulphonylureas, biguanides, insulin, thiazolidinediones and 
others either single or in combination was documented. Also the 
use of drugs which could influence Mg homeostasis- diuretics 
was also documented. 
7. The Magnesium evaluation included- a serum Magnesium 
sample and 24 hour urine magnesium by atomic absorption 
spectrophotometry. 
8. A dietary history by a 24 hour recall was done to estimate the 
approximate daily consumption of magnesium for 14 patients. 
The dietary Mg intake was computed by multiplying the Mg 
content of the specified serving of each food item by the 
frequency of its daily consumption and summing overall items. 
(Annexure B). 
9. Also the drinking water content of magnesium was estimated for 
10 patients, by atomic absorption spectrophotometry. 
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Definitions: 
The following were the cut offs taken for defining the groups: 
1. Definition of diabetes mellitus:- 
• Fasting          > 126mg% (Fasting is defined as no calorie intake for 
atleast 8 hours) 
• 2 hours Postprandial glucose > 200mg% 
• symptoms of diabetes plus Random Blood Glucose>200mg% 
 
     2.  Glycemic control: - HbA1c <7- was taken as good control 
                          - HbA1c >7 were divided into the following groups 
                                      -7-8.9- group1 
                                      -9-10.9- group 2 
                                      -11-12.9- group 3 
                                      ->13- group 4  
 
     3. Hypertension: - defined as a) systolic blood pressure more than 140 mm of Hg 
                                                    b) diastolic blood pressure more than 90 mm of Hg 
                                                    c) patient who had been on antihypertensive drugs 
  
     4. Dyslipidemia- If LDL was >100mg/dl 
                        Or Triglycerides >150mg/dl 
 
 
     5.  Body mass Index- defined as a) Malnourished if BMI was less than 18 kg/m2 
                                                         b) Normal if BMI was between 18 and 25 kg/m2 
                                                         c) Overweight if BMI was between 25 and 30 kg/m2 
                                                         d) Obese if BMI was more than 30 kg/m2 
 
     6. Peripheral neuropathy- If Monofilament threshold >/= 4gm, in either of the feet 
                           - If biothesiometer threshold was >/= 25 mV 
Semmes- Weinstein Monofilament 
    Light touch sensation was tested using 2gm, 4gm and 10 gm monofilaments over 
metatarsal head/ ball of the great toe (while testing; only mild pressure was applied so 
that the filament was not bent). Loss of sensation over 2gm was considered as peripheral 
neuropathy in the lower limbs. Loss of protective sensation in the lower limb is indicated 
by 10 gms loss of sensation. The patient is asked to say “yes” each time he or she feels 
the filament. Failure to feel the filament at four of ten sites is 97% sensitive and 83% 
specific for identifying loss of protective sensation. This method has sufficient 
reproducibility, when used as screening test for diabetic foot ulcerations.  
 
Biothesiometer- Quantitative Sensory Testing 
    It provides a quick and reliable assessment of vibration thresholds, which gives an 
objective measure of the progress of diabetic peripheral neuropathy. However, detection 
of impairment of vibration sense using tuning fork (128 Hz) is adequate, when a 
biothesiometer is not available. If the value is above 25V, that could be taken as evidence 
of neuropathy. 
       7. Nephropathy- Microalbuminuria was present if the urine microalbumin was 
between 30 and 300 microgm/mg of creatinine or 30- 300 mg/day in a 24 hour urine 
collection.  
               - Overt nephropathy/macroproteinuria– If urine microalbumin >300 
microgm/mg of creatinine or 24 hour urine protein was more than 500mg/24 hours, or if 
there was evidence of renal failure as evidenced by raised serum creatinine (3) 
        
      8. Retinopathy- Present or absent as confirmed by an Ophthalmologist and the 
diagnosis was made in the presence of microaneurysms, dot and blot hemorrhages and 
evidence of macular edema, or any patient who LASER/ intervention for retinal 
detachment/ vitreous hemorrhage. 
 
     9. Cardiovascular disease- Any of the following features qualified:  
              a) Past history of acute coronary syndrome 
              b) Stable angina 
              c) History of PTCA/ CABG 
              d) TMT positivity  
  
10. Cerebrovascular disease- Any of the following features 
              a) History of transient ischemic attack/ stroke 
              b) Carotid stenosis- either carotid bruit or Doppler proven 
 
11. Peripheral vascular disease: - Any of the following features 
             a) Absent peripheral pulses 
             b) Claudication pain 
             c) History of gangrene/ amputation 
  
12. Renovascular disease: - Any of the following features  
              a) Renal bruit 
              b) Doppler evidence of renal artery stenosis 
 
13. Hypomagnesemia- was defined as a serum magnesium level less than or equal to 1.7 
mg/dl. 
 
14. 24 hour urine magnesium – The normal range was taken as 70 to 120 mg/dl, and any 
value more than 120 mg/dl was taken as inappropriate magnesuria. 
 
15. Dietary content of Magnesium- The recommended daily allowance was 320 mg/day 
for women and 420 mg/day for men as per Krause’s text book of food, nutrition and diet 
therapy (82). 
 
16. Magnesium content of drinking water- At least 10mg/dl of magnesium content was 
considered adequate. 
 
 
Magnesium estimation 
       Magnesium estimation was done by the Atomic Absorption Spectrophotometry 
released by the Perkin- Elmer Corporation in September 1996. 
Analysis- For the determination of magnesium, dilute the serum or plasma sample in a 
1:100 ratio, with deionised water as the diluent.  
Principle- The machine consists of a sample introduction system, an excitation source 
(hollow magnesium lamp), nebuliser and flame burner, chopper and detector. An atom of 
magnesium is capable of absorbing light energy characteristic of magnesium. The 
radiation generated from the hollow magnesium lamp, whose cathode is made of 
magnesium is made to pass through the flame containing magnesium and the photons are 
absorbed. The degree of absorption is proportional to the concentration of magnesium in 
the flame (the flame also serves as the means of supporting the atoms in the light path). 
The measured difference between the light intensity passing around the flame and that 
passing through the flame defines absorption and is used to determine the concentration 
of magnesium in the atomized solution (83).  
 The magnesium standard used which was used in our study was 5 mg/l, and a QC 
(quality control) was estimated on a daily basis. The mean QC was 2.3 and the mean 
coefficient of variation was 1.8 during the time period of this study. 
 
 
 
 
 
  
Statistical analysis 
 Continuous variables are presented using mean ± standard deviation and categorical 
variables are presented using frequencies and percentages. Continuous variables were 
compared using Student’s t test. Association between categorical variables was assessed 
using Chi-square test with Yates continuity correction. All statistical analyses were 
performed using SPSS 11.0 for windows. A p-value < 0.05 was considered to be 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
             A total of 138 diabetic patients were evaluated for the prevalence of 
hypomagnesemia between March 2008 and May 2008. All were diabetics who were 
attending the diabetic endocrine out patient clinic at the Christian Medical College 
Hospital (CMCH), Vellore. All of them had a complete evaluation for diabetic co-
morbidities and complications- both microvascular and macrovascular. Of these, 126 
patients had given 24 hour urine urine magnesium samples, to look for inappropriate 
magnesuria. A careful dietary history was taken for about 20 of the patients and drinking 
water magnesium content was estimated in 4 of the hypomagnesemic and 6 
normomagnesemic patients.  All the patients who had low serum magnesium, were 
informed about their low serum magnesium levels via phone, and the need for 
supplementation. The baseline characteristics of the patients, are included in table 1. 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Patient recruitment for study 
 
 
 
 
Baseline characteristics: 
            The baseline characteristics of the patients are presented in Table 9. Of the 
population, 52.9 % of the patients were male. Most of the patients- 51% were between 40 
and 60 years age. The mean HbA1c for the whole group was 8.3+/- 1.74 g%. About 19% 
were well controlled diabetics, with HbA1c less than 7g%, and about 33% were poorly 
controlled diabetics with HbA1c more than 9%, as shown in graph 2. The mean BMI of 
the group was 25.4. Almost 53% were overweight, and about 46% had normal BMI. 
There were patients between 22 and 78 years age, and the mean age of the group was 
about 52.5. The mean duration of diabetes was 85.2 months (with a standard deviation of 
76.6). About 50% of the population had been having diabetes for less than 5 years. 
Among the patients, 42 % were hypertensive and 77% had dyslipidemia.  
160 patients  included from  
the diabetic clinic 
138 patients given the serum magnesium samples 
127 patients had given the 24 hour urine magnesium 
samples 
20 patients had not given the serum samples 
2 patients had not completed the evaluation for co-
morbidities and complications 
             With regard to the profile of diabetic complications, 35% had neuropathy, 45% 
had evidence of microalbuminuria and 17% had retinopathy (given in table 10). 10 % of 
the patients had frank nephropathy as evidenced by either renal failure or 
macroalbuminuria. Among the macrovascular complications, ischemic heart disease was 
seen in 13 % of the patients, only 1.4 % had evidence of cerebrovascular disease and 
none had peripheral vascular disease.  
           Most of the patients had been on oral hypoglycemic drugs- mainly sulphonylureas 
and biguanides, and some were on insulin in combination with the oral drugs. 66% were 
on sulphonylureas, 75% were on metformin (biguanides), and 29% were on insulin (as 
given in table 11). 
           Among the drugs which are known to affect magnesium metabolism- diuretics and 
statins were widely used, (about 12% and 36% respectively). 
           Most of the patients were following the dietary instructions, as advised by the 
dietician in the diabetic out patient clinic. Most of the population depended on the 
government water supply for drinking water, and a minority depended on mineral water 
(processed water). 
 
 
 
 
 
 
 
Table 9. Baseline characteristics of all the study patients  
Baseline characteristics All patients 
Total number 
Sex 
     Male 
     Female 
Age (mean in years) 
 
Age categories: 
  20-40 yrs 
  40-60 yrs 
60-80 yrs 
BMI (mean) 
BMI in subgroups (%) 
       <18 
        18-25 
        >25 
HbA1c (mean) 
HbA1C groups 
         <7 
          7-9 
          9-11 
         11-13 
         >13 
Duration of diabetes mellitus in months 
Duration categories: 
    Upto 60 months 
    61-120 months 
    121- 240 months 
    > 241 months 
138 
 
73 (52.9%) 
65 (47.1%) 
52.5+/-11.9 (range from 22 to 78) 
 
23 (16.7%) 
71 (51.4%) 
44 (31.9%) 
25.4 +/-3.9 kg/m2 
 
2 (1.4%) 
63 (45.7%) 
73 (52.9%) 
8.30 +/- 1.74 
 
26 (18.8%)  
66 (47.8%) 
30 (21.7%) 
13 (9.4%) 
3 (2.2%) 
85.2 +/-76.6 
 
74 (53.6%) 
31 (22.5%) 
26 (18.8%) 
7 (5.1%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 2; The distribution of diabetic patients in different HbA1C groups is as 
follows: 
 
 
1.HbA1c <7g% 
2.HbA1c 7-9g% 
3.HbA1c 9-11g% 
4.HbA1c 11-13g% 
5.HbA1c >13g% 
 
 
 
 
 
Table 10: Diabetic complications and co-morbidities 
 
Co-morbidities and 
complications 
Total number of patients Confidence intervals 
Co-morbidities 
Hypertension 
Dyslipidemia 
Diabetic microvascular 
complications 
-Microalbuminuria 
-Nephropathy 
-Neuropathy by 
monofilament 
-Neuropathy by 
biothesiometer 
-Motor neuropathy 
-Retinopathy 
Diabetic macrovascular 
complications 
-Ischemic heart disease 
-Cerebrovascular disease 
-Peripheral vascular disease 
-Renovascular disease 
 
58 (42%) 
107 (77.5%) 
 
 
62 (44.9%) 
14 (10.1%) 
49 (35.5%) 
 
23 (16.7%) 
 
33 (23.9%) 
24 (17.4%) 
 
 
18 (13%) 
2 (1.4%) 
0 
1 (0.7%) 
 
33.77, 50.23 
70.53, 84.47 
 
 
36.6, 53.2 
5.07, 15.13 
27.51, 43.48 
 
10.48, 22.92 
 
16.78, 31.02 
11.07, 23.73 
 
 
7.39, 18.61 
0, 3.36 
 
0, 2.09 
 
Distribution of patients in different groups based 
on HbA1c values
1
2
3
4
5
 Table 11. Drug profile of the study population 
Drug No of patients (%) Confidence intervals 
Diabetic drugs 
   Sulphonylureas 
   Biguanides 
   Thiazolidinediones 
   Meglinides 
   Alpha glucosidase inhibitor 
   Insulin 
 
Other drugs which could affect 
magnesium excretion 
   Antibiotics- Aminoglycosides 
a. Carbenicillin 
b.  Amphotericin 
   Diuretics 
   Alcohol 
   Cisplatin 
   Digoxin 
   Methotrexate 
   Statin 
   Theophylline 
 
 
92 (66.7%) 
104 (75.4%) 
9 (6.5%) 
0 
1 (0.7%) 
40 (29%) 
 
 
 
0 
0 
0 
17 (12.3%) 
2 (1.4%) 
0 
2 (1.4%) 
0 
50 (36.2%) 
1 (0.7%) 
 
 
58.84, 74.56 
68.21, 82.59 
 
 
0, 2.09 
21.43, 36.57 
 
 
 
 
 
 
6.82, 17.78 
0, 3.36 
 
0, 3.36 
 
28.18, 44.22 
0, 2.09 
 
 
 
 
 
 
 
 
 
 
 
Prevalence of hypomagnesemia: 
A total of 7 patients out of 138, had hypomagnesemia with a prevalence of 5.1% (CI- 
1.43 , 8.77%). The profile of the hypomagnesemic patients is described in table 12. 
There were 7 diabetics with hypomagnesemia, with serum levels less than 1.7 mg/dl. The 
lowest serum Mg level observed in this group was 1.2 mg/dl. They did not have any 
features of cardiovascular and neuromuscular manifestations such as palpitations, 
documented arrhythmias, tremors and other abnormal movements. All of them had 
HbA1c levels more than 7g%, of which 4 were poorly controlled group as defined by 
HbA1c value more than 9g%. Their mean HbA1c value was 8.98 +/- 1.37 g%. Their 
mean duration of diabetes was about 83 months. All 7 of them had dyslipidemia, as 
evidenced by LDL > 100g% and triglycerides >150g%, and about 42% had hypertension. 
     Of the 7 patients, microalbuminuria and retinopathy was seen in about 42% of the 
group, and nephropathy, neuropathy as evidenced by monofilament and motor 
neuropathy was seen in about 28%. Among the macrovascular complications, ischemic 
heart disease was seen in 2 patients(28%).  The only patient in the whole population who 
had renal vascular disease had hypomagnesemia. 
       Out of the 7 hypomagnesemic patients, 6 had been on insulin, and 5 had been on 
sulphonylureas and metformin. Among the drugs which could affect magnesium 
metabolism, 3 had been on statins and 1 had been on a diuretic.  
 
 
 
 
Table 12: Profile of patients with hypomagnesemia 
Characteristics Number (%)                          
Sex 
     Male 
     Female 
Age (mean in years) 
   <40 yrs 
   >40 yrs 
BMI (mean) 
BMI in subgroups (%) 
       <18 
        18-25 
        >25 
HbA1c (mean) 
HbA1C groups 
         <7 
          7-9 
          9-11 
         11-13 
         >13 
Duration of diabetes mellitus in months 
      <60 months 
      60-120 months 
      121-240 months 
      >240  months 
Hypertension 
Dyslipidemia 
Diabetic complications 
-Microalbuminuria 
-Nephropathy 
-Neuropathy by monofilament 
-Neuropathy by biothesiometer 
-Motor neuropathy 
-Retinopathy 
-Ischemic heart disease 
-Cerebrovascular disease 
-Peripheral vascular disease 
-Renovascular disease 
 
4 (57.1%) 
3 (42.9%) 
56.57 +/-16.65 
1 (14.3%) 
6 (85.7%) 
24.17 +/-3.22 
 
0 
4 (57.1%) 
3 (42.9%) 
8.98 +/-1.37 
 
0 
3 (42.9%) 
3 (42.9%) 
1 (14.3%) 
0 
113.29 +/-56.74 
1 (14.3%) 
3 (42.9%) 
3 (42.9%) 
0 
3 (42.9%) 
7 (100%) 
 
3 (42.9%) 
2 (28.6%) 
2 (28.6%) 
1 (14.3%) 
2 (28.6%) 
3 (42.9%) 
2 (28.6%) 
0 
0 
1 (14.3%) 
 
 
 
 
Predictive factors for hypomagnesemia in diabetes 
        The baseline characteristics and the drug history among patients with and without 
hypomagnesemia are outlined in tables 13 and 14. 
       Baseline characteristics were compared among patients with and without 
hypomagnesemia. There was no significant difference in age, gender and body mass 
index (BMI) values between the 2 groups. Though the HbA1c was 8.98 in the 
hypomagnesemic group, which was higher compared to 8.3 in the normomagnesemic 
group, the difference was not statistically significant (p value 0.31). All the 
hypomagnesemics had HbA1c values more than 7, of which 57% had HbA1c more than 
9, as compared to the proportion of patients who were normomagnesemic, although this 
difference was not significant. Though the duration of diabetes was shorter in the 
hypomagnesemics, compared to the normals, (83.6 months vs. 113.2 months), it was not 
statistically significant (p value= 0.32). 
      The proportion of patients with hypertension was comparable in both the groups. 
Although 100% of the hypomagnesemics were dyslipidemic, and about 76% among the 
normomagnesemics were dyslipidemic, the difference was not statistically significant (p 
value=0.14). The details with regard to co-morbidities and complications are given in 
table 14. 
      With regard to the diabetic complications, microalbuminuria was present in about 
42.9% among the hypomagnesemics, and 45% among the normomagnesemics, and this 
difference was not statistically different (p=0.91). Among the hypomagnesemics, 28.6% 
had nephropathy and among the normomagnesemics, 9.2% had nephropathy, however 
this difference was approaching significance (p=0.09). Retinopathy prevalence among the 
hypomagnesemics and normomagnesemics was 42% and 16% respectively,  and this 
difference was also approaching statistical significance  (p=0.07). There was also no 
significant difference among the 2 groups, with regard to neuropathy. Since the overall 
number of patients with cerebrovascular disease and renovascular disease was only 2 and 
1 respectively, the tests of statistical significance were not applied.  The only patient with 
renovascular disease had hypomagnesemia.  
 
Table 13: Baseline characteristics of patients with and without hypomagnesemia 
Baseline characteristics Patients with 
hypomagnesemia 
Patients without 
hypomagnesemia 
P value 
Total number 
Sex 
     Male (n=73) 
     Female (n=65) 
Age (mean in years) 
BMI (mean) 
BMI in subgroups (%) 
       <18 (n=2) 
        18-25 (n=64) 
        >25 (n=72) 
HbA1c (mean) 
HbA1C groups 
         <7 (n= 26) 
          7-9 (n=66) 
          9-11 (n=30) 
         11-13 (n=13) 
         >13 (n=3) 
Duration of diabetes mellitus 
in months 
 
7 
 
4 (57.1%) 
3 (42.9%) 
56.57+/-16.65 
24.17+/-3.22 
 
0 
4 (57.1%) 
3 (42.9%) 
8.98+/-1.37 
 
0 
3 (42.9%) 
3 (42.9%) 
1 (14.3%) 
0 
83.67+/-77.4 
 
 
131 
 
69 (52.7%) 
62 (47.3%) 
52.37+/-11.68 
25.48+/-3.95 
 
2 (1.5%) 
60 (45.8%) 
69 (52.6%) 
8.30+/-1.75 
 
26 (19.8%) 
63 (48.1%) 
27 (20.6%) 
12 (9.2%) 
3 (2.3%) 
113.29+/-56.74 
 
 
 
 
 
 
 
 
 
0.82 
 
0.37 
0.39 
 
0.81 
 
 
0.31 
 
0.51 
 
 
 
 
0.32 
 
 
 
 
 
 
Table 14: Diabetic co-morbidities and complications in patients with and without 
hypomagnesemia 
 
Diabetic comorbidities and 
complications 
Patients with 
hypomagnesemia 
(n=7) 
Patients without 
hypomagnesemia 
(n=131) 
P value 
Diabetic comorbidities 
     Hypertension (n=58) 
     Dyslipidemia (n=107) 
Diabetic complications 
-Microalbuminuria (n=62) 
-Nephropathy (n=14) 
-Neuropathy (n=82) 
-Retinopathy (n=24) 
-Ischemic heart disease (n=18) 
-Cerebrovascular disease (n=2) 
-Peripheral vascular disease 
-Renovascular disease (n=1) 
 
3 (42.9%) 
7 (100%) 
 
3 (42.9%) 
2 (28.6%) 
3 (42.9%) 
3 (42.9%) 
2 (28.6%) 
0 
0 
1 (14.3%) 
 
55 (42%) 
100 (76.3%) 
 
59 (45%) 
12 (9.2%) 
79 (60.3%) 
21 (16%) 
16 (12.2%) 
2 (1.5%) 
0 
0 
 
0.96 
0.14 
 
0.91 
0.97 
0.35 
0.07 
0.21 
0.74 
 
 
Predictive factors- Drug  history 
The proportion of patients in each group, who were on sulphonylureas and metformin 
were comparable. 14% of the hypomagnesemic population and about 6% of the 
normomagnesemic population were on thiazolidinediones, but the difference was not 
statistically significant.  However, a significant proportion of the hypomagnesemic group 
was on insulin (85%) as compared to the normomagnesemic group (26%),and that 
difference was statistically significant with a p value of 0.001.  
  With regard to the other drugs, which affected the magnesium homeostasis, diuretics 
were widely used, but the proportion of patients on diuretics were also comparable 
between the 2 groups, as shown in table 15.  
Table 15. Drug list compared between patients with and without hypomagnesemia 
Drug No of patients with 
hypomagnesemia(%) 
No of patients 
without 
hypomagnesemia 
(%) 
P 
value 
Diabetic drugs 
   Sulphonylureas 
   Biguanides 
   Thiazolidinediones 
   Meglinides 
   Alphaglucosidase                     
inhibitor 
   Insulin 
 
Other drugs 
Antibiotics 
c. Aminoglycosides
d. Carbenicillin 
e. Amphotericin 
   Diuretics 
   Alcohol 
   Cisplatin 
   Digoxin 
   Methotrexate 
   Statin 
   Theophylline 
 
5 (71.4%) 
5 (71.4%) 
1 (14.3%) 
0 
0 
 
6 (85.7%) 
 
 
 
0 
0 
0 
1 (14.3%) 
0 
0 
0 
0 
3 (42.9%) 
0 
 
87 (66.4%) 
99 (75.6%) 
8 (6.1%) 
 
1 (0.8%) 
 
34 (26%) 
 
 
 
 
 
 
16 (12.2%) 
2 (1.5%) 
0 
2 (1.5%) 
0 
47 (35.9%) 
1 (0.8%) 
 
0.78 
0.80 
0.39 
 
 
 
0.001 
 
 
 
 
 
 
0.87 
0.74 
 
0.74 
 
0.71 
0.82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of the Mean Magnesium values in different subgroups of patients 
 
The mean magnesium concentration of the total number of 138 diabetics, was 2.06+/-
0.23mg/dl. The table shows the mean serum total Mg concentration in different subsets 
of patients, like gender, presence or absence of co-morbidities and complications. The 
mean magnesium concentration was higher in the males than in females (2.1mg/dl vs 
2.02mg/dl respectively), and this difference was statistically significant with a p value of 
0.04. In different subgroups with regard to presence and absence of co-morbidities and 
complications, the mean Mg concentration was comparable. Even the mean Mg 
concentration between the different HbA1c groups were comparable. 
Table 16:  The mean Mg in different subgroups with and without the complications 
and comorbidities 
Subgroups of Patients Mean Serum Magnesium Standard Deviation P Value
Sex- Male 
       -Female 
2.1 
2.02 
0.25 
0.2 
0.044 
HbA1c </= 7 
             7 to 9 
             9 to 11 
            11 to 13 
            > 13 
2.05 
2.09 
2.02 
2.03 
2.02 
0.19 
0.2 
0.31 
0.27 
0.16 
NS 
Hypertension- Yes 
                     - No 
2.05 
2.08 
0.22 
0.24 
0.42 
Dyslipidemia- Yes 
                     - No 
2.07 
2.06 
0.24 
0.2 
0.86 
Retinopathy- Yes 
                   - No 
1.98 
2.08 
0.26 
0.22 
0.08 
Microalbuminuria- Yes 
                             - No 
2.06 
2.06 
0.23 
0.23 
0.93 
Nephropathy - Yes 
                      - No 
2.04 
2.07 
0.3 
0.22 
0.75 
Neuropathy- Yes 
                   - No 
2.08 
2.05 
0.24 
0.23 
0.39 
IHD- Yes 
       - No 
2.07 
2.06 
0.34 
0.21 
0.87 
CVA-  Yes 
        - No 
1.86 
2.07 
0.04 
0.23 
0.23 
Renovascular disease-Y 
                                  -N 
1.7 
2.06 
0 
0.22 
0.12 
 
 
 
Drugs and mean magnesium concentration 
 
Table 17 shows the subsets of population with and without the drugs, and their mean 
magnesium concentration. It was interesting to find a significantly lower mean Mg value 
among the patients who had been on thiazolidinediones- 1.91 mg/dl, when compared to 
the patient group who was not on the same-2.07 mg/dl, and the p value was 0.04. With 
regard to the other drug groups, the mean Mg concentrations were comparable between 
the 2 groups. 
 
Table 17- The mean Mg concentration in subgroups of different drugs 
 
Drug  Mean Magnesium Standard Deviation P Value 
Sulphonylurea -yes 
                        - no 
2.04 
2.09 
0.22 
0.25 
0.22 
Biguanides -yes 
                  - no 
2.05 
2.08 
0.22 
0.27 
0.69 
Thiazolidinediones-yes 
                               - no 
1.91 
2.07 
0.28 
0.23 
0.04 
Insulin-yes 
           - no 
2.02 
2.08 
0.3 
0.2 
0.14 
Diuretics -yes 
                - no 
2.09 
2.05 
0.27 
0.23 
0.57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the 24 hour urine magnesium samples: 
127 patients among the study patients had given 24 hour urine samples for the estimation 
of magnesuria. The normal range was taken as 70 to 120 mg per day (76).  About 44.8% 
had features of hypermagnesuria, as shown in Table 18. Renal magnesium handling is 
very efficient so as to accommodate for the changes in serum magnesium, and hence 
hypomagnesuria may be relevant only in patients with hypomagnesemia. However, 
among the patients with hypomagnesemia, inappropriate magnesuria was observed in 
only 1 patient (14.3%), whereas it was observed in about 46.6% among the 
normomagnesemic group. This difference was however not statistically significant.  
 
 
Table 18: 24 hour urine magnesium excretion in relation to serum Mg concentration 
24 hours urine 
magnesium 
No of patients with 
hypomagnesemia 
(total =7) 
No of patients 
without 
hypomagnesemia 
(total = 120) 
P value 
0-70mg 1 (14.3%) 10 (8.3%)  0.17 
71-120 mg 5 (71.4 %) 54 (45%)  
>120 mg 1 (14.3%) 56 (46.7%)  
 
 
 
 
 
 
Diuretics and 24 hour urine magnesium: 
It is well known that the urinary Mg excretion is increased, if the patient is on diuretics 
(28, 84). In table 19, a comparison of the 24 hour urine Mg was done between the 
patients who had been on diuretics and who had not been on diuretics. 14 patients out of 
the 127 patients for whom 24 hour urine Mg values were available, had been on diuretics. 
Out of the 14 patients, 57% had hypermagnesuria, whereas in the patients who had not 
been on diuretics, 44% had hypermagnesuria, but this difference was also not statistically 
significant. 
 
Table 19: 24 hour urine magnesium in relation to diuretic use 
 
24 hour urine magnesium No. of patients 
on diuretics 
(total = 14) 
No. of patients 
Not on diuretics 
(total=113) 
P Value 
0-70mg 0 12(10.6%) 0.376 
71-120mg 6(42.8%) 51(45.1%)  
>120mg 8(57.2%) 50(44.3%)  
 
 
 
 
 
 
 
 
 
 
Estimation of dietary intake of Magnesium 
About 15 patients were asked for a 24 hour recall for diet, and an approximate estimation 
was made, regarding their intake of daily intake of magnesium from the available 
information. Most of them were following the dietary instructions as provided by the 
dieticians of the diabetic endocrine out patient clinic. Their average daily intake was 
calculated, and the method of estimation is attached as Annexure B. The average daily 
intake of magnesium in diet of our population is given in table 20. 
 
 
Table 20: Mean daily dietary consumption of magnesium  
 Mean 24 hour diet 
intake in 
hypomagnesemic 
patients (n=7) 
Mean 24 hour diet 
intake in 
normmagnesemic 
patients (n=7) 
P value 
24 hour dietary Mg 
Intake in mg/day 
403 430 0.28 
 
 
There was no significant difference in dietary magnesium intake between the 
hypomagnesemic and the normomagnesemic patients. 
 
 
 
 
 
 
Estimation of drinking water Magnesium content 
Drinking water samples were collected for 10 patients, of which 4 had hypomagnesemia 
and the other 6 were normomagnesemic. 
        Ideal drinking water samples should contain atleast 10 mg/dl of magnesium, as 
evidenced from western literature. It was found that 4 out of the 10 samples, had 
magnesium content < 10 mg/dl, as shown in table 21. 
       2 out of the 4 hypomagnesemic patients had low water content of magnesium, which 
could contribute to their low serum magnesium values. The patients who had low water 
content of magnesium, were consuming mineral water. The others who had high/ 
adequate water content of magnesium, had been drinking  borewell water. Most of the 
water supply in Vellore is  hard water, which has a  high content of magnesium and 
calcium. Thus the low prevalence of hypomagnesemia in our population, could be 
attributable partly to the high magnesium content of water.  However there was no 
significant difference between the average Mg content of drinking water between the 
patients with hypomagnesemia and those with normal serum magnesium values. 
 
 
 
 
 
 
 
 
 Table 21: Magnesium content in drinking water in hypomagnesemic and 
normomagnesemic groups 
 The Mg concentration in the 
hypomagnesemics 
(4 patients) 
The Mg concentration in the 
normomagnesemics 
(6 patients) 
P value 
 38.7 mg/l (borewell water) 21.7 mg/l (borewell water)  
 
 
1 mg/l (mineral water) 3.6 mg/l  
 21.5 mg/l (borewell water) 28.1 mg/l (borewell water)  
 3.4 mg/l (mineral water) 4.6 mg/l  
  41.4 mg/l (borewell water)  
  41.5 mg/l(borewell water)  
Mean 
concentration 
of Mg in 
drinking 
water 
16.15 mg/l 23.45 mg/l 0.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Profile of the hypomagnesemic patients with regard to the factors which could 
influence the serum Mg values 
 
Table 22 shows the details of the 7 hypomagnesemic patients, including  the serum Mg 
levels, and the other factors which include- quantitative dietary intake of Mg for 24 
hours, drinking water content of magnesium,  24 hour urine Mg excretion in mg/day and 
the drug history- among which diuretic is the most important. The details of drinking 
water content is available only for 4 of the hypomagnesemic patients. It is obvious that 
P1- who had a serum Mg level 1.7, had a higher 24 hour urine Mg excretion compared to 
the other patients, and he had a history of diuretic intake also, which could probably 
explain the high 24 hour urine Mg excretion. P2 had no obvious explanation for the low 
serum Mg value. P3 who had the least serum Mg level- 1.2mg/dl, had the lowest value 
for Mg concentration in the drinking water and 24 hours diet content. P4 had a very low 
drinking water content of magnesium. The last 3 patients, who had serum values >/=1.58, 
had a reasonable dietary intake except, a borderline low content in P5, and there was 
drinking water content information available only for P6, which was adequate. There was 
no clear cause for the low serum Mg level in P7, as there was no information available on 
the drinking water content of Mg. 
Correlation between hypomagnesemia and hypokalemia- Since hypomagnesemia can 
also be associated with other electrolyte abnormalities, the serum potassium values were 
estimated in patients with hypomagnesemia. Of the 5 patients out of the 7 
hypomagnesemics, for whom serum potassium values were available, all had normal 
potassium levels.  
 
 
 
 
 
 
 
Table 22: Hypomagnesemic patients- correlation with regard possible mechanisms  
 
for hypomagnesmia 
 
Patient 
 
Serum Mg 
in mg/dl 
Serum 
K in 
mmol/l 
Diet Mg 
mg/day 
Water 
Mg 
In mg/l 
24hr urine 
Mg 
In mg/day 
Diuretic 
use 
P1 1.7 4.8 420 NA 147/2490 Yes 
P2 1.46 0 408 38.7 70/810 No 
P3 1.2 5.1 348 1 85/1580 No 
P4 1.61 3.5 423 3.4 72/3150 No 
P5 1.66 3.5 388 NA 111/2360 No 
P6 1.58 0 426 21.5 120/1950 No 
P7 1.68 4.4 410 NA 99/2050 No 
 
          
 
 
 
 
 
 
DISCUSSION: 
 
      138 patients who were diagnosed to have diabetes mellitus were assessed for 
hypomagnesemia, and the estimated prevalence was only 5.1% (7/138 patients). The 
overall prevalence of hypomagnesemia reported in our study, was lower than that 
reported in other studies of 25% from Delhi, and about 47% from other studies from the 
West. This study was different from other prevalence studies, in that other factors such as 
diabetic complications, co-morbidities, drug history, approximate daily intake of 
magnesium and the magnesium content of drinking water was also documented. 
     The mean magnesium concentration of our diabetic population was 2.06 +/- 
0.23mg/dl, which was higher compared to other populations of diabetics (for example 
1.93mg/dl at Bikaner (37), 1.81mg/dl at Chandigarh (38) and 1.44mg/dl at Delhi (39)- 
from India and from abroad- 1.48mg/dl at Mexico (6) ). 
     In view of the very low prevalence of hypomagnesemia in our study group, tests of 
statistical significance did not show any major difference, and also multivariate analysis 
was not possible. 
     The reasons for lower prevalence of hypomagnesemia in our diabetic population could 
be the following: 
A smaller proportion of patients with poorly controlled diabetes with HbA1c levels 
>9gm% in our study population. The mean HbA1c of our study population was about 
8.3(+/-1.74), as compared to 12.2 (+/- 0.6) % , in the study published by Yajnik et al, 
who found a significantly lower mean serum Mg level of 2.01 mg/dll compared to 2.1 
mg/dl in the non-diabetics (87). Also, Lima et al had found significantly lower Mg 
content – 1.77+/-0.4 mg/dl, in poorly controlled diabetic group with HbA1c level of 
about 9.3+/-2.6% and a prevalence of 47.7% was detected among the diabetic population 
(27).  
    Magnesium being a predominantly intracellular cation, serum Mg represents less 
than 1% of the total body Mg content, so it may not reflect the actual magnesium status 
of the body. However, most of the studies have used serum total magnesium for total 
body magnesium estimation. Some studies have found that serum ionized Mg and 
intracellular Mg may not correlate with serum total Mg content, as suggested by Resnick 
etal, who found that both ionized Mg and intracellular Mg were lower in diabetics, 
whereas serum total Mg content was not significantly low. Ionised Mg and intracellular 
Mg were 0.552+/-0.008mmol/l and 184+/-13.7mmol/l in the diabetics, compared to non 
diabetics where the values were 0.630+/-0.008mmol/l and 223.3+/-8.3mmol/l 
respectively. Furthermore, a close relationship was observed between serum ionized Mg 
and intracellular Mg (p<0.001), but not with serum total Mg content(88). However, most 
of the studies so far have used serum total magnesium, rather than intracellular or ionized 
magnesium. 
  The patients were evaluated for probable cause for this low prevalence of 
hypomagnesemia, including 24 hour dietary intake of Mg and the Mg content of  
drinking water:  
      Diet: The approximate dietary intake of Mg over a 24 hour period was assessed for 
14 patients, of which 7 were hypomagnesemic and the other 7 were normomagnesemic. 
The major sources of magnesium in the food supply are dairy products (20%), grain 
products (20%), meat, poultry and fish (15%), legumes, nuts and soya products (13%) - 
most of these have been restricted in a diet prescribed for diabetics, which could be 
contributing to the higher prevalence of hypomagnesemia in diabetics. The recommended 
daily intake of Mg is 320-420mg/day. Our population had a mean intake of above 
400mg.day, which is much higher than in the studies elsewhere and this could be the 
explanation for a low prevalence of hypomagnesemia in our diabetic population. The 
normal diet in our population has been based on unprocessed foods- because most of the 
population consumes only 5% milled rice, whereas in urban areas 10% milled rice is 
being consumed. The mean magnesium intake was lower in the group with 
hypomagnesemia (403mg/day), whereas it was 430mg/day among the normomagnesemic 
patients, but this difference was not statistically significant. In a study done by Song etal, 
the median intake of magnesium, in their population was found to be 326mg/day and 
there was a modest inverse association between magnesium intake and risk of developing 
diabetes among middle aged women. 
       Drinking water:    The contribution of drinking water Mg to overall Mg intake is 
about 10% (50).  The average daily intake of water in our population was about 1.5-2 
litres per day. More than 60% of the patients depend on tap water, which was mainly hard 
water, which has high Mg content (i.e, >10mg/dl), and most of the normomagnesemic 
people had a water Mg content of >20mg/dl. This may explain the low prevalence of 
hypomagnesemia in our population. The average mean water content of magnesium was 
16.15mg/l in the hypomagnesemic group and 23.45 mg/dl in the normomagnesemic 
group, and there are studies to show that upto 40-50% of waterborne Mg may be 
absorbed compared to about 30% from food (66, 67).  It has been documented in various 
studies that cardiovascular mortality is associated with the degree of hardness of water 
(85). Thus waterborne magnesium would have relative importance, particularly in 
patients whose diets are relatively deficient in magnesium. 
          The proportions of patients who had been on the different hypoglycemic drugs, 
was similar in both hypomagnesemics and normomagnesemics, except that a 
significantly higher proportion of hypomagnesemics were on insulin (85% compared to 
26% among the normomagnesemics) and this difference was highly significant (p value -
0.001). However when comparing the actual levels of Mg in patients on insulin (2.02 +/- 
0.3 mg/dl) as against those not on insulin (2.08+/- 0.2 mg/dl) there was no significant 
difference. Yajnik had found that insulin treated diabetics had a lower and non-insulin 
treated diabetics had higher plasma magnesium concentrations (2.01 mg/dl in the insulin 
group and 2.28 mg/dl in the non-insulin group, (p<0.01) (86). It was also interesting to 
find that the mean magnesium concentration was significantly lower in the patients on 
thiazolidinediones- 1.91mg/dl, compared to 2.07mg/dl among the patients not on the 
same, and the p value was 0.04. This finding was in contrary to the study published by 
Guerroro, where the diabetics on pioglitazone were found to have a significantly higher 
serum Mg content, than the diabetics who were not on pioglitazone (1.93 +/- 0.16 mg/dl 
in the pioglitazone group, whereas it was 1.74 +/- 0.25 mg/dl in the control group, p < 
0.0001) (87).  There is not much of evidence in literature with regard to this association 
between thiazolidinedione and serum Mg content- it may be that hypomagnesemia is 
more common in long standing diabetics- in whom thiazolidinediones also may be 
indicated. 
          With regard to the drugs which may influence the magnesium metabolism, the 
proportion of the population who had been on diuretics was comparable between the 
hypomagnesemic and the normomagnesemic groups, and the mean Mg concentration 
among the diuretic users and diuretic nonusers was also comparable, unlike in many other 
studies where there was a significantly lower mean Mg among the diuretic users (1.87 
mg/dl among diuretic users vs. 1.89 mg/dl among the diuretics nonusers (28). And the 
proportion of patients who had been statins- which are known to be associated with 
hypomagnesemia, was also similar between the 2 groups. The mean concentration of Mg 
was similar in the populations who had been on the other drugs. 
        With regard to baseline characteristics, the study population was comparable to the 
populations involved in other studies. The mean age was 52.5 +/- 11.9 which was similar 
to most other studies, for example in Yajnik etal’s study it was about 54.7 +/- 1.4 years 
(86). The mean BMI was 25.4 +/- 3.9 in our study population, which was also similar in 
Yajnik etal’s study (26.7+/-0.5) (86). The duration of diabetes in our study was 85.2 
months, which was similar to Lima etal’s study, where the mean duration was about 7.3 
years (+/-5.4). So our study population was in fact comparable with other study 
populations, with regard to most of the baseline characteristics, except for a lower mean 
HbA1c, showing reasonably good overall diabetic control. 
          Another interesting finding was a significantly higher mean Mg concentration 
among males than females (2.1 mg/dl and 2.02 mg/dl respectively) with a p value 0.04, 
which was similar in many other studies, where also there was a higher prevalence of 
hypomagnesemia in females (40, 86). 
          In this study, there seemed to be a higher prevalence of dyslipidemia among the 
hypomagnesemics than normomagnesemics, but the difference was not statistically 
significant. This higher prevalence of dyslipidemia was probably because dyslipidemia 
was defined as LDL>100mg/dl or serum triglycerides >150 mg/dl, which are 
recommended cut offs for patients with diabetes (3, 10), and were much lower than the 
cut off taken elsewhere. Similarly prevalence of hypertension was also comparable 
between the 2 groups. 
          With regard to diabetic microvascular complications, our study showed no  
significant association between the proportion of patients in both hypomagnesemics and 
normomagnesemic, except in retinopathy and nephropathy, where the difference was 
approaching statistical significance (p = 0.07 and 0.09 respectively). Similarly the mean 
magnesium concentration was comparable between the groups with and without the 
microvascular complications, except in retinopathy, where the difference was 
approaching statistical significance (Mean Mg-1.98 mg/dl and 2.08 mg/dl in patients with 
and without retinopathy respectively, p=0.08). This was similar to a study by McNair 
etal, where the serum Mg level among the cohort with diabetes had an inverse correlation 
with retinopathy (44). 
            There was no significant difference between the proportion of patients with regard 
to microalbuminuria, and also the mean Mg concentrations between the groups with and 
without microalbuminuria was comparable, unlike the results from a study by Corsonello 
etal, who had shown a significantly lower serum ionized Mg value in patients with 
microalbuminuria and nephropathy, compared to patients without albuminuria (45), 
which were 0.86 +/- 0.12 mg/dl, 0.84 +/- 0.09 mg/dl and 1.08 +/- 0.04 mg/dl,  with a 
significant p value <0.001.  
            Neuropathy both sensory and motor, were also evaluated in the diabetic 
population and the means and proportions were compared, which showed no statistically 
significant difference between the hypomagnesemic and the normomagnesemic groups. 
This was in contrast to the study by Rodrieguez-Moran and Guerrero- romero, who had 
proven that hypomagnesemia was present in a higher proportion of patients with foot 
ulcers, than patients without foot ulcers (93.9% of the 33 patients with diabetic foot 
ulcers compared with 73.1% of the 66 patients without diabetic foot ulcers; p value= 
0.02). Also subjects with foot ulceration had lower serum magnesium levels (1.48 +/- 
0.33) than those in the control group (1.68 +/- 0.32), p <0.001 (7).     
          With regard to macrovascular complications, higher prevalence of coronary artery 
disease was found in the overall population, but the mean Mg concentration and the 
proportion of hypomagnesemics were almost similar. The prevalence of cerebrovascular 
disease and renovascular disease was too low, for any significant difference. 
 
 
 
 
 
 
 
 
 
 
 
  
 
LIMITATIONS 
1. The sample size was too small to conduct multivariate analyses in view of the 
extremely low prevalence of hypomagnesemia in our population. 
2. The dietary intake and drinking water magnesium content estimation could be 
done only in a limited number of patients due to logistical reasons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
The important conclusions of this study are as follows: 
1. The prevalence of hypomagnesemia in our diabetic population was detected to be  
5.1% (CI- 1.43%- 8.77%). 
2.  The mean magnesium concentration in our diabetic population was 2.06+/-0.23 mg/dl. 
3.  All the 7 hypomagnesemic patients had HbA1c levels above 7 g% 
4. The mean HbA1c was higher in the hypomagnesemic group (8.98 g% +/- 1.37), than in 
the normomagnesemic group (8.30 g% +/- 1.75), though the difference was not 
statistically significant (p value-0.31). 
5. Males had a higher mean magnesium concentration than females (2.1mg/dl in males 
and 2.02 mg/dl in females), with a p value 0.04. 
6. The proportion of patients with retinopathy and neuropathy in the hypomagnesemics 
was higher than the normomagnesemic population, and the p values were approaching 
statistical significance (p 0.07 and 0.09 respectively). 
7.  The difference between the mean magnesium concentration between the patients with 
and without retinopathy, was also approaching statistical significance (p-0.08). 
8. The profile of the microvascular- neuropathy, microalbuminuria and macrovascular 
complications between the hypomagnesemic and normomagnesemic diabetics were 
comparable, and there was no statistically significant difference. The mean magnesium 
concentration was also comparable between the groups with and without each of the 
micro and macrovascular complications.   
9. The proportion of patients who had been on insulin was higher in the hypomagnesemic 
groups than the normomagnesemic group with a p value of 0.001. 
10. The patients who had been on thiazolidinediones had a significantly lower 
magnesium concentration (1.91 mg/dl) compared to the patients who had not been on 
thiazolidinediones (2.07 mg/dl), p value was 0.04. 
11. 24 hour urine magnesium excretion was almost within normal range among the 
hypomagnesemic patients. 
12. There was no statistically significant difference in the urinary magnesium excretion 
between the diuretic users and diuretic non-users. 
13. There was a significantly higher daily intake of magnesium in our population than in 
other studies averaging  >400mg/day. It was higher in the normomagnesemic group- 430 
mg/day, compared to 403 mg/day in the hypomagnesemic group, but the difference was 
not statistically significant. 
14. The magnesium concentration of drinking water is higher in Vellore, in view of the 
tapwater being hardwater, on which most of our population depends, which could also 
explain the low prevalence of hypomagnesemia in our diabetic population.  
 
In summary, although hypomagnesemia is a potentially reversible metabolic problem in 
diabetes, it does not appear to be a significant problem in our diabetic population, when 
compared to the other studies from India and the west. The causes of this low prevalence 
could be probably due to the high magnesium content of drinking water, and high daily 
dietary intake of magnesium in our population. The other factors like the diabetic 
complications and co-morbidity profile of the hypomagnesemics and normomagnesemic 
groups were comparable, except for nephropathy and retinopathy which were 
approaching significance. 
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ANNEXURE A: CLINICAL PROFORMA FOR EVALUATION OF 
PATIENTS 
INCLUDED IN STUDY OF HYPOMAGNESEMIA AND ITS ASSOCIATION 
WITH DIABETES MELLITUS 
A. Demographic details: - 
1. Name of the patient 2. Date of first visit 
3. Hospital Number  4. Age  5. Sex M / F 
6. Address for communication 
Mobile number- 
 
B. Clinical evaluation for Diabetes and its comorbidities: - 
Duration of 
Diabetes Mellitus 
 Duration of 
OHA failure 
 Type of Diabetes 
mellitus 
I /  II 
C. Clinical examination- General: - 
Weight 
in Kg 
 Height 
in cm 
 Body 
mass 
Index 
 Waist 
circumference
 Waist 
hip 
ratio 
  
Pulse rate  Blood pressure              /         mm of Hg 
D. Clinical evaluation for Diabetes microvascular and macrovascular complications: - 
Circle the appropriate response. 
NEUROPATHY Sensory – 
Monofilament- 
R-      , L- 
Biothesiometer 
R-     , L- 
Motor Sensorimotor Foot ulcer 
AUTONOMIC 
NEUROPATHY 
Postural drop  
In Blood 
Pressure 
Impotence   
NEPHROPATHY Urine 
microalbumin 
 
24 hour urine 
protein 
Serum 
creatinine 
 
RETINOPATHY Non 
proliferative 
retinopathy 
Proliferative  
Diabetic  
retinopathy 
LASER  
Therapy/ 
CSME 
Vitreous 
hemorrhage/ 
Retinal 
detachment  
ISCHEMIC HEART  
DISEASE 
Past 
Myocardial 
Infarction/ACS
Stable  
angina 
TMT 
positivity 
PTCA/ 
CABG 
CEREBROVASCULAR  
DISEASE 
TIA CVA Carotid 
stenosis 
Bruit/ 
Doppler 
abnormality 
PERIPHERAL  
VASCULAR DISEASE 
Absent pulses Claudication 
pain 
Gangrene Amputation 
COMORBIDITIES Hypertension Dyslipidemia 
RENOVASCULAR Renal bruit Renal artery 
stenosis 
  
 
 
 
E. Drug history- Circle the drugs in use 
Sulphonyl 
ureas 
Biguanides Thiazolidinediones Meglinides Alpha 
glucosidase 
inhibitors 
Insulin 
F. Investigations: - (Normal values in brackets) 
AC / PC   
(<110/ <140 mg 
%) 
 HbA1c     
(<7) 
 Serum 
Sodium  
 Serum 
Potassium 
 
Lipid profile- 
TC/ TG/ HDL/ 
LDL  
 24 hour urine 
protein/Urine 
microalbumin
 Serum 
Magnesium 
 Serum 
Calcium  
 
24 hour urine 
magnesium 
 
H. Circle the clinical manifestations if present 
Palpitations/ 
dysrhythmias 
Weakness Muscle 
cramps 
Altered 
mental 
status 
Seizures/ 
Jitteriness 
 
 
L. FINAL DIAGNOSIS 
DIABETES MELLITUS CONTROL 
GOOD / POOR 
-- NEPHROPATHY    Y / N 
-- RETINOPATHY    Y / N 
-- NEUROPATHY    Y / N 
-- ISCHEMIC HEART DISEASE    Y / N 
-- CEREBROVASCULAR DISEASE    Y / N 
-- PERIPHERAL VASCULAR DISEASE    Y / N 
HYPERTENSION 
   Y / N 
DYSLIPIDEMIA    Y / N 
 
Antibiotics 
          -
Aminoglycosides 
          - Carbenicillin 
          - Amphotericin   
Diuretics- Acetazolamide 
f. Furosemide 
g. Thiazide 
              
Alcohol Cisplatin 
Digoxin Methotrexate Statins Theophyllines 
Other drugs- Specify  
ANNEXURE- B: MAGNESIUM CONTENT IN SPECIFIC 
FOOD ITEMS 
(From the book- Nutritive value of Indian foods- Authors- Gopalan C,  
Ramasanstri B.V, National Institute of Nutrition) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Food stuff Quantity Amount  Contents  Magnesium content-
mg/100gm of the food 
item 
RICE 1 CUP 200 GMS  Parboiled- 157 
5% milled rice- 90 
10% milled rice- 64 
1DLI 1 LARGE 50 GM Rice 
Black gram dal 
 
130 
DOSA 1 number 50 gms Rice 
Black gram dal 
Fat 
 
 
 
CHAPPATHI 1 number 50 gms Wheat flour 
Fat 
Whole wheat-138 
Wheat- vermicelli-42 
BREAD 1 slice 20-30 gms   
SAMBAR ½ CUP 100 gms Tuar dal 
Veg 
Fat 
90 
31- 44 
VEGETABLES ½ CUP 100 gms  31-44 
MILK ½ CUP 100 ml  33 
EGG 1 50gms  5 
MEAT 6-8 piees 70 gms  16-25 
FISH 1 slice 65 gms  13 
CHICKEN  70 gms  25 
excel
Hospital No Age  Sex 
Duration 
of 
diabetes BMI 
R 
monofilament 
L 
monofilament 
R 
biothesiometer 
 
Motor 
Urine
micro
244290a 45 2 48 28.5 4 4 10 12 0 
253867b 49 1 84 26.3 2 2 20 10 0 
954788b 57 2 180 22.8 2 2 18 20 0 
743968c 25 1 12 23.7 2 2 20 20 0 
858301b 43 1 24 31.5 10 4 31 12 0 
953664a 42 2 264 31.2 4 4 14 14 0 
523527a 51 1 168 22.5 2 2 14 16 0 
398162c 64 1 360 30.1 10 4 16 18 1 
963533c 44 2 12 28.3 2 2 19 24 0 
048503a 49 2 60 26.1 2 2 14 10 0 
160369b 74 1 180 25.9 2 2 18 12 0 
844576b 62 2 72 22.2 4 4 18 20 1 
808117b 68 1 144 36.4 10 10 28 34 1 
796537a 42 2 84 29.4 2 2 14 12 1 
017452d 53 1 12 20.9 2 2 6 8 0 
865250b 47 1 84 29.4 2 2 16 9 0 
610233c 68 1 120 22.5 2 2 14 14 0 
940607c 69 2 168 24.7 6 6 80 60 1 
208151d 49 2 48 28.1 2 2 24 11 0 
471150a 50 2 192 24 2 2 16 14 0 
219090d 40 1 4 23 2 2 8 4 0 
389380c 60 2 60 23.1 2 2 13 9 0 
907372c 59 2 48 26.2 4 4 10 10 0 
724779b 68 2 60 24.7 2 2 14 12 0 
840378 69 2 276 23.9 4 4 3 3 0 
744172c 72 1 240 22.64 10 10 40 40 1 
611653c 61 1 108 20.4 10 10 16 17 1 
071186a 50 2 264 30.8 4 4 14 30 1 
173601d 61 1 60 21 4 4 29 35 0 
664010 51 2 216 30.4 2 2 16 13 0 
233871d 70 1 36 24.5 4 4 39 43 1 
079028c 58 1 96 21.1 2 2 8 6 0 
380808c 63 2 180 34.1 4 4 17 7 0 
574886c 58 1 300 28.1 4 4 22 32 1 
776861b 52 1 60 24.6 10 10 12 15 1 
617445b 59 2 120 24.8 4 4 13 24 0 
308443b 58 1 84 24.4 4 4 21 30 0 
202469d 22 2 1 18.8 2 2 15 12 0 
141602d 37 2 36 29.1 2 2 20 13 0 
394763a 78 1 60 25.4 4 4 20 20 0 
400011c 58 1 168 22.2 10 10 23 19 1 
643728c 43 1 48 17.9 4 4 23 28 0 
230358d 61 2 36 20.2 4 2 18 11 0 
873300a 56 2 84 27.3 2 2 8 8 1 
300163c 38 2 12 28.1 2 2 12 14 0 
057599D 63 1 36 38.9 2 4 14 16 1 
668766b 40 1 36 26.3 2 2 15 12 0 
709781B 33 2 36 27.1 2 2 14 26 0 
507073b 43 2 3 26.1 2 2 17 15 0 
032624d 35 1 12 25.1 2 2 20 15 0 
089383d 60 1 12 21.5 2 2 21 10 0 
466570c 47 2 12 27 2 2 13 10 0 
017452d 53 2 12 21 2 2 6 8 0 
684048c 60 1 180 25.8 4 4 5 5 0 
105937b 57 1 1 26.8 2 2 12 12 0 
390993b 61 2 132 26.1 2 2 21 17 0 
706096b 43 1 24 25.4 2 2 10 7 0 
647035C 65 1 240 21 10 10 24 29 1 
023537d 61 1 48 23.53 2 2 20 15 0 
ANNEXURE C- Patient data 1 
ANNEXURE C-  PATIENT DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s. creatinine Retinopathy IHD CVA 
Peripheral 
vascular 
disease 
Renovascular 
disease Sulphonylureas Biguanides ThiazolidinedionesMeglinides 
Alp
inh
0.7 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 0 1 0 0
0.8 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 1 0 0
1.1 0 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 0 1 0 0
1.4 1 0 0 0 0 1 1 1 0
0.9 1 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 0 1 0 0
0.8 0 0 0 0 0 1 0 0 0
1.1 1 1 0 0 1 1 1 0 0
0.8 0 0 0 0 0 1 0 0 0
0.8 0 1 0 0 0 0 1 0 0
0.6 1 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 1 0 0
0.6 0 0 0 0 0 0 0 0 0
0.8 0 0 0 0 0 0 1 0 0
0.9 0 0 0 0 0 1 1 0 0
1.1 0 0 0 0 0 0 1 0 0
0.7 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.6 0 0 0 0 0 1 0 0 0
1 1 1 0 0 0 1 1 0 0
2.3 1 0 0 0 0 0 0 0 0
1.2 0 0 0 0 0 1 1 1 0
1.1 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 1 0 0
0.8 0 0 0 0 0 1 1 1 0
1.1 0 0 0 0 0 0 0 0 0
0.9 0 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 1 1 0 0
1.1 0 1 0 0 0 1 1 0 0
1.1 0 1 0 0 0 0 0 0 0
1.1 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 0 0 0 0
0.7 0 0 0 0 0 0 1 0 0
1.3 0 0 0 0 0 1 0 0 0
1 1 1 0 0 0 1 1 0 0
2 1 0 0 0 0 1 0 0 0
1 0 1 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 0 0 0
0.9 0 1 0 0 0 0 0 0 0
0.8 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
1.2 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 0 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 0 1 0 0
0.9 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 1 0 0
0.9 1 0 0 0 0 0 1 0 0
1 1 0 0 0 0 1 1 0 0
1 0 0 0 0 0 0 1 0 0
0.7 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 1 1 0 0
0.8 1 0 0 0 0 0 1 0 0
0.9 1 1 0 0 0 1 1 1 0
1.2 0 1 0 0 0 0 1 0 0
0.9 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 1 1 0 0
1.2 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 1 1 0 0
1.2 0 1 0 0 0 1 0 0 0
0.8 0 0 0 0 0 1 0 0 0
0.8 0 0 0 0 0 1 1 1 0
0.8 0 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 1 1 0 0
1.1 1 0 0 0 0 1 0 1 0
0.9 0 0 0 0 0 0 0 0 0
1.8 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 0 0
0.7 1 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 0 1 0 0
0.9 1 1 0 0 0 1 0 0 0
0.9 0 0 0 0 0 1 1 0 0
1 0 0 1 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 1 0
0.8 0 0 0 0 0 1 1 0 0
1.4 0 1 0 0 0 1 0 0 0
0.7 0 0 0 0 0 1 0 0 0
1 0 0 0 0 0 1 1 0 0
1 0 1 0 0 0 0 1 0 0
0.7 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 0 0 0 0
1.2 0 0 0 0 0 0 0 0 0
1.1 0 0 0 0 0 0 1 0 0
0.6 0 0 0 0 0 1 1 1 0
0.8 0 0 0 0 0 0 0 0 0
0.7 1 1 0 0 0 1 1 0 0
0.7 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 0 0 1 0
0.7 0 0 0 0 0 1 1 0 0
0.6 1 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 0 0 0 0
0.9 0 0 0 0 0 1 1 0 0
0.9 0 0 0 0 0 1 1 0 0
1.1 0 1 0 0 0 1 1 0 0
1.5 0 0 0 0 0 1 0 0 0
0.8 0 0 0 0 0 0 1 0 0
1.2 0 1 0 0 0 1 0 0 0
3.9 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 1 0 0
1.5 1 0 0 0 0 0 0 0 0
0.9 0 0 0 0 0 1 1 0 0
1 1 0 0 0 0 1 1 0 0
1.1 0 0 0 0 0 1 1 0 0
0.6 0 0 0 0 0 1 0 0 0
0.9 0 0 0 0 0 0 1 0 0
0.9 0 0 0 0 0 1 1 0 0
2.6 1 0 0 0 0 0 0 0 0
0.7 0 0 0 0 0 0 0 0 0
0.8 1 0 0 0 0 1 1 0 0
0.7 0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 1 0 0
0.8 0 0 0 0 0 1 1 0 0
1.1 1 0 0 0 0 1 1 0 0
0.8 0 0 0 0 0 1 0 0 0
0.8 0 0 0 0 0 1 1 0 0
2.1 0 0 0 0 0 1 1 0 0
1 0 0 0 0 0 0 0 0 0
2.1 0 1 0 0 0 1 1 0 0
0.9 1 0 1 0 0 0 1 0 0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alcohol cisplatin Digoxin Methotrexate Statin Theophylline
s 
HbA1c Total choles Triglycerides HDL LDL
0 0 0 0 1 0 7.4 186 87 32
0 0 0 0 1 0 9.7 153 129 33
0 0 0 0 0 0 6.9  
0 0 0 0 0 0 7.8 154 133 34
0 0 0 0 0 0 7.2 210 327 38
0 0 0 0 1 0 8.5 110 112 42
0 0 0 0 0 0 6.1 203 150 46
0 0 0 0 0 0 7.8 194 104 39
0 0 0 0 0 0 7  
0 0 0 0 0 0 7.8 194 107 40
0 0 0 0 1 0 8.2  
0 0 0 0 0 0 9.6  
0 0 0 0 1 0 5.9  
0 0 0 0 1 0 7.1 237 128 42
0 0 0 0 0 0 7 128 127 30
0 0 0 0 1 0 6.9 203 104 41
1 0 0 0 0 0 6.2 141 105 29
0 0 0 0 1 0 7.8  
0 0 0 0 0 0 9.6  
0 0 0 0 0 0 7.3 165 104 31
0 0 0 0 1 0 7.1 226 171 38
0 0 0 0 0 0 7.4 195 173 41
0 0 0 0 1 0 7.3  
0 0 0 0 0 0 6.7 245 319 52
0 0 0 0 1 0 9.4 219 112 53
0 0 0 0 1 0 7.1 195 195 42
0 0 0 0 0 0 7.8 163 196 28
0 0 0 0 0 0 6.9 242 223 54
0 0 0 0 0 0 6.8 120 62 28
0 0 0 0 1 0 8.5 269 145 59
0 0 0 0 0 0 11.9 182 87 48
0 0 0 0 0 0 7.1  
0 0 0 0 0 0 9 226 162 45
0 0 0 0 1 0 7.8 124 66 32
0 0 0 0 0 0 7.3  
0 0 0 0 1 0 8.1 188 156 47
0 0 0 0 1 0 11.5 143 180 30
0 0 0 0 0 0 11.3 162 82 39
0 0 0 0 0 0 7.5  
0 0 0 0 1 0 6.6 207 219 36
0 0 0 0 0 0 9.8  
0 0 0 0 0 0 6.6 100 44 36
0 0 0 0 0 0 9 136 74 51
0 0 0 0 0 0 10.2 135 145 30
0 0 0 0 0 0 6.1 183 85 40
0 0 0 0 1 0 7.3 181 134 30
0 0 0 0 0 0 6.9 222 445 50
0 0 0 0 0 0 7.9 166 279 41
0 0 0 0 0 0 9.9  
0 0 0 0 0 0 6.2 164 61 38
0 0 0 0 0 0 7.8 143 172 33
0 0 0 0 0 0 8 136 70 30
0 0 0 0 0 0 7 128 127 30
0 0 0 0 0 0 7.9 176 154 40
0 0 0 0 0 0 11.1 179 138 31
0 0 0 0 1 0 7.6 235 81 41
0 0 0 0 0 0 7 177 323 36
0 0 0 0 0 0 6.3 184 102 37
0 0 0 0 0 0 7 80 40 24
0 0 0 0 0 0 8.3 165 314 34
0 0 0 0 0 0 6.3  
0 0 0 0 1 0 6.8 128 135 34
0 0 0 0 0 0 8.5 103 98 34
0 0 0 0 0 0 12.3  
0 0 0 0 0 0 8.9  93 0
0 0 0 0 0 0 6.3 205 362 35
0 0 0 0 0 0 9.4 155 135 31
0 0 0 0 0 0 13  
0 0 0 0 0 0 9.6 145 180 35
0 0 0 0 1 0 11.7 192 149 33
0 0 0 0 0 0 7.3  
0 0 0 0 0 0 8.6 195 384 34
0 0 0 0 0 0 7.3 151 159 35
0 0 0 0 0 0 11.4  101
0 0 0 0 1 0 9  166
0 0 0 0 0 0 11.2  106
0 0 0 0 1 0 7.5 162 194 37
0 0 0 0 0 0 11.8 207 154 36
0 0 0 0 0 0 6.8 160 125 26
0 0 0 0 0 0 10.1 144 154 37
0 0 0 0 1 0 7.6 133 186 32
0 0 0 0 0 0 7.5 249 342 42
0 0 0 0 0 0 7.3 197 108 41
0 0 0 0 0 0 4.3  
0 0 0 0 1 0 8.7 248 142 52
0 0 0 0 0 0 6.5 176 76 52
0 0 0 0 1 0 11.1 157 73 33
0  0 0 0 0 6.4 190 148 41
0 0 0 0 1 0 7.8 145 191 28
0 0 0 0 0 0 9.7 171 120 37
0 0 0 0 1 0 10.1 137 222 33
0 0 0 0 1 0 9.8 275 121 52
0 0 0 0 1 0 7.8 168 228 36
0 0 0 0 1 0 8 175 73 38
0 0 0 0 1 0 7.7 223 122 46
0 0 0 0 0 0 9.1 171 86 37
0 0 0 0 0 0 7.1 133 228 32
0 0 0 0 0 0 8 199 196 41
0 0 0 0 0 0 7.2  286
0 0 0 0 0 0 11 170 534 34
0 0 0 0 0 1 9.3 137 166 27
0 0 0 0 0 0 6.1 183 188 39
0 0 0 0 0 0 9.9 165 61 43
0 0 0 0 1 0 6.4 149 109 41
0 0 0 0 1 0 6.1 206 142 41
0 0 0 0 0 0 8.2 188 52 59
0 0 0 0 0 0 10.1  
0 0 0 0 1 0 7 202 174 37
0 0 0 0 0 0 6  
0 0 0 0 1 0 7.7 283 184 61
0 0 0 0 0 0 9 164 129 43
0 0 0 0 1 0 9.7 202 175 33
0 0 0 0 0 0 7.2 132 201 24
0 0 0 0 1 0 12.3 269 105 55
0 0 0 0 0 0 13  
0 0 0 0 0 0 8 233 695 57
0 0 0 0 0 0 8.6 203 148 44
0 0 0 0 1 0 11.7 200 146 41
0 0 0 0 0 0 7 216 97 43
0 0 0 0 0 0 10.3 154 451 41
0 0 0 0 1 0 10.1  
0 0 0 0 1 0 8.6 138 178 35
0 0 0 0 1 0 10.4 223 153 42
0 0 0 0 0 0 7.8 179 146 33
0 0 0 0 0 0 9.2 199 210 35
0 0 0 0 1 0 9.6 171 202 35
0 0 0 0 0 0 8.6  
1 0 0 0 1 0 9.2  
0 0 0 0 1 0 7.3 225 160 46
0 0 0 0 0 0 6.2 192 165 43
0 0 0 0 1 0 10 239 172 48
0 0 0 0 0 0 8.1 182 162 39
0 0 0 0 0 0 8.2 238 79 47
0 0 0 0 0 0 13 208 125 38
0 0 1 0 1 0 7.3 179 126 30
0 0 0 0 1 0 7 186 132 51
0 0 1 0 1 0 7.3 179 126 30
0 0 0 0 1 0 9.8 108 148 33
 
 
 
 
